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-ABSTRACTCardiovascular disease is the leading cause of mortality in The United States and
Europe, accounting for approximately half of all deaths. The most common form of
cardiovascular disease is atherosclerosis, which is characterized by the formation of fatty
atheromatous plaques that can grow to occlude the vessel lumen, thus causing ischemia
distal to the occlusion. This is commonly treated using balloon angioplasty, which is
usually done in conjunction with the deployment of a stent. Stent deployment helps hold
the vessel open following the local injury caused by balloon inflation and prevents elastic
recoil and subsequent negative remodeling. Stenting has been shown to significantly
reduce restenosis rates from approximately 20-50% without a stent to about 10-30% with
stent deployment.
However, restenosis still remains the main cause of long-term stent failure. In
basic terms, a balloon angioplasty procedure is a forceful displacement of an
atherosclerotic lesion serving to widen the vessel lumen to increase blood flow. This
procedure causes stretching of the vessel wall, tears in the atherosclerotic plaques, and
general damage to the vessel in turn signaling a complex cascade of thrombosis,
inflammation, intimal thickening, and vascular remodeling. Stent deployment also
further complicates the immunological response by triggering a foreign body response
from the implantation of a biomaterial into the body. When performing an angioplasty
procedure, particularly in conjunction with stent deployment, a certain degree of vascular
injury is inevitable. However, the initial injury can be further complicated by the body’s
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local reaction to the implanted biomaterial, the severity of which can ultimately dictate
the degree of restenosis and subsequently affect procedural success.
The proliferative response of VSMCs to the various afore mentioned stimuli
results in the formation of often copious amounts of neointimal tissue, generally known
as intimal hyperplasia. The formation of this new tissue, primarily consisting of VSMCs
of the synthetic phenotype and their subsequent extracellular matrix, is the sole causation
of in-stent restenosis since the stent serves to prevent elastic recoil and negative
remodeling.
This doctoral research program is focused on endovascular stent biomaterials
science and engineering. Overall, this doctoral project is founded on the hypothesis that
smooth muscle cell hyperplasia, as an important causative factor for vascular restenosis
following endovascular stent deployment, is triggered by the various effects of stent strut
contact on the vessel wall including contact forces and material biocompatibility. In this
program, a dynamic in vitro model of a stented blood vessel aimed at evaluating the
effect of stent strut material selection, and surface coating on smooth muscle cell
response was developed.
The in vitro stented artery model was validated through the proliferation of
VSMC in contact with stent struts. Additionally, it was demonstrated that, with respect
to known biocompatible materials such as Nitinol and 316L stainless steel, DNA
synthesis and α-actin expression, as indicators of VSMC phenotype, are independent of
stent material composition. Furthermore, hydroxyapatite was shown to be a
iii
	
  

biocompatible stent surface coating with acceptable post-strain integrity. This coating
was shown in a feasibility study to be capable of serving as a favorable drug delivery
platform able to reliably deliver locally therapeutic doses of bisphosphonates, such as
alendronate, to control VSMC proliferation in an in vitro model of a stented blood vessel.
This stent coating/drug combination may be effective for reducing restenosis as a result
of VSMC hyperplasia in vivo.
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-CHAPTER 1Introduction and Background

1.1 Introduction
Cardiovascular disease is the leading cause of mortality in The United States and
Europe, accounting for approximately half of all deaths.[1, 2] The most common form of
cardiovascular disease is atherosclerosis. Atherosclerosis is an inflammatory disease
affecting the large and medium sized arteries and can occur in any part of the body. It is
characterized by the formation of fatty atheromatous plaques that can grow to occlude the
vessel lumen, thus causing ischemia distal to the occlusion. Appendix A gives a more in
depth background of blood vessel biology as well as the progression and diagnosis of
atherosclerosis. Atherosclerosis is commonly treated using balloon angioplasty, which is
usually done in conjunction with the deployment of a vascular stent. Stent deployment
provides structural rigidity to the vessel wall, thereby helping to hold the vessel open
following the local injury caused by balloon inflation and prevent elastic recoil and
negative remodeling. In fact, stenting has been shown to significantly reduce restenosis
rates from approximately 20-50% without a stent to about 10-30% with stent
deployment.[3] However, this still leaves significant room for improvement. As of
2001, it was estimated that approximately 80% or more of all angioplasty procedures
were done in conjunction with the deployment of a stent.[4] As a result, the stent market
has undergone tremendous growth in recent years and was estimated to be a 5.6 billion
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dollar world market in 2006.[5] This makes research involving the optimization of
treatments for occlusive vascular disease using vascular stents a very important and
potentially profitable endeavor.
Charles Dotter is widely credited with the invention of the intraluminal metallic
stent similar to the form that is known today.[4, 6, 7] He was also recognized as the first
to successfully perform the technique of percutaneous transluminal stent deployment by
implanting a “coilspring graft” stent in the femoral artery of a canine model in 1969.[810] Later, Andreas Grüntzig, building on the work of Dotter, developed a balloon
catheter in 1977 that allowed the use of the percutaneous transluminal angioplasty
(PCTA) procedure for the dilation of peripheral arteries.[4, 7, 8, 11] Contrary to Dotter,
Grüntzig had a more conservative personality and presented his findings in a more
cautious approach that kept with the norms of the time. This allowed Grüntzig to bring a
greater acceptance of angioplasty as a viable alternative to the more invasive vascular
surgeries of the period.[8]
As mentioned previously, the deployment of an intravascular stent in conjunction
with the angioplasty procedure reduces the risk of restenosis within the range of 10-30%
versus the 20-50% restenosis risk of angioplasty alone.[3] However, restenosis still
remains the main cause of long-term stent failure. In the most basic terms, a balloon
angioplasty procedure is a forceful displacement of an atherosclerotic lesion serving to
widen the vessel lumen area to increase blood flow. In so doing, this procedure causes
stretching of the vessel wall, tearing in the atherosclerotic plaques, and general damage to
the vessel.[4] This injury in turn signals a complex cascade of elastic recoil, thrombosis,
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inflammation, intimal thickening, and vascular remodeling.[4] Elastic recoil and
negative remodeling are the primary causative factors of restenosis when vessel
expansion is done by balloon only because of the lack of structural strength provided by
the stent, which maintains the expanded luminal diameter. Indeed, the post-procedural
lumen diameter is the most telling predictor of the expected long term lumen diameter.[4]
As mentioned previously, the deployment of a vascular stent greatly reduces the
incidence of elastic recoil by serving to mechanically hold the vessel open. However, in
the treatment of calcified and highly fibrous lesions, acute stent recoil of up to 15-30% is
commonly observed.[4] Stent deployment also further complicates the immunological
response by triggering a foreign body response from the implantation of a biomaterial
into the body. When performing an angioplasty procedure, particularly in conjunction
with stent deployment, a certain degree of vascular injury is inevitable. However, the
initial injury can be further complicated by the previously mentioned inflammatory
response, the severity of which can ultimately dictate the degree of restenosis and
subsequently affect procedural success.
Following balloon angioplasty, it is common to experience significant local
damage to the endothelium or often a near complete denudation of the endothelial
layer.[4, 12] The acute reaction is an increased thrombogenic response because of the
loss of inhibitory effects of the endothelium on thrombus formation and exposure of the
thrombogenic underlying collagen and sub-endothelial matrix.[4, 13] It also triggers an
inflammatory response and the extrinsic coagulation pathway due to injury to the vessel
wall. To further amplify this thrombogenic response, the implanted biomaterial itself
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also triggers the intrinsic coagulation pathway and amplifies the inflammatory response.
With the use of current anticoagulant and anti-platelet therapy, thrombus formation to
such an extent as to occlude the vessel lumen is relatively rare, and is not the primary
determinant of long term procedural success.[4] Alternately, it is the thrombus formation
and recruitment of inflammatory cells leading to high local concentration of growth
factors such as cytokines and PDGF, as well as fibrin that triggers a mitogenic and
chemotactic response from smooth muscle cells.[4, 14]

The proliferative response of

VSMCs to the various afore mentioned stimuli results in the formation of often copious
amounts of neointimal tissue, generally known as intimal hyperplasia. The formation of
this new tissue, primarily consisting of VSMCs of the synthetic phenotype and their
subsequent extracellular matrix, is the sole causation of in-stent restenosis since the stent
serves to prevent elastic recoil and negative remodeling.[4]
As stated previously, injury to the vessel wall triggers thrombosis and
inflammation as the first stages of wound healing.[13] Following this, the next step
observed is often intimal thickening. Intimal thickening is caused by the recruitment of
VSMCs into the intima by chemotactic and mitogenic substances from thrombosis and
inflammation.[12, 13] These substances cause a local influx of migrating VSMCs to the
area followed by cellular proliferation. Additionally, the growth factor rich thrombus
present at the stenting site can also form a favorable scaffold, which protrudes into the
lumen, for the colonization and growth of VSMCs.[15, 16] Additionally, these
proliferative VSMCs are of a synthetic phenotype that also exhibit increased extracellular
matrix production. These factors lead to thickening of the vessel wall and in some cases
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the lumen diameter is reduced to the extent that a follow up interventional therapy is
needed to restore vessel patency. The thickening of the intima to restrict blood flow
following angioplasty is given the general term restenosis or, when experienced in a
stented vessel, in-stent restenosis. The degree of restenosis varies from case to case
under similar circumstances due to mechanisms that are not yet fully understood.
However, some factors such as host response to the implanted biomaterial and
biomaterial thrombogenicity as well as degree of vascular injury upon stent deployment
have been shown to have a significant influence.[17-19] In addition to these factors,
there are others that are thought to influence restenosis, such as contact stresses and
rheological factors. Low wall shear stress and wall shear stress gradients, which are
discussed in more detail in Appendix B, are thought to be directly linked to VSMC
hyperplasia and subsequent restenosis. However, these factors can be modified by
variations in stent design. Therefore, careful consideration in stent design, paying special
attention to reduction of vessel injury, biocompatibility of materials, and hemodynamics
of blood flow, could lead to reduced restenosis and better long-term patency.
Immediately following stent implantation, various blood proteins bind to the
surface of the stent.[20] Blood cells then accumulate at the site of stent deployment
within minutes and thrombus formation occurs shortly thereafter. VSMCs then respond
to chemotactic factors from injury and clot formation, migrate into the area, and soon
begin to proliferate.[4, 20, 21] These synthetic VSMCs proliferate over a period of a few
months when the majority of the restenosis takes place.[4, 21, 22] It is generally
accepted that restenosis will present itself within the first six to nine months if it is going
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to occur, with restenosis initiated after twelve months being rare.[4, 22] This is followed
by a somewhat quiescent period several years after placement in which the neo-intimal
material is composed primarily of extracellular matrix with a few scattered VSMCs.
However, the degree of restenosis varies from case to case even under similar
circumstances due to mechanisms that are not yet fully understood.[4, 23]
The use of in vitro modeling can be very useful to gain an understanding of the
mechanisms by which smooth muscle cells undergo the observed phenotypic shift
following stent implantation. For this reason, many researchers are developing complex
dynamic testing systems in order to closely model how SMCs of various lineages are
stimulated by their native environment and what effects can be observed by changing
variables in this dynamic system. These systems commonly employ the use of flowinduced shear stress, mechanical stretching of cells, and/or compressive loading. This
may be done as a one-time stimulus to the cells, such as stretch induced injury for an
angioplasty model, or may be applied cyclically to mimic the cyclic flow and/or
mechanical stretch experienced in vivo. A review of the effects stemming from the
application of these various mechanical stimuli either singularly or in combination is
given in Appendix B. The in vitro system developed in our research group, which is able
to subject cells to compressive loading using a model stent strut of varying material
composition while mimicking the in vivo environment of concurrent cyclic strain and
flow, is the subject of the current project and will be evaluated further in the coming
chapters.
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1.2 Research Hypothesis
This doctoral research project is focused on endovascular stent biomaterials science
and engineering. Overall, it is founded on the hypothesis that smooth muscle cell
hyperplasia, as an important causative factor for vascular restenosis following
endovascular stent deployment, is triggered by the various effects of stent strut contact on
the vessel wall including contact forces and material biocompatibility. A dynamic in vitro
model of a stented blood vessel aimed at evaluating the effect of stent material selection,
and surface treatment on smooth muscle cell response has been developed. This research
hypothesis is verified using the aims detailed below.

•

Aim 1: Computational Characterization of Simulator Contact Forces and
Evaluation of Synthetic Phenotypic Behavior of Vascular Smooth Muscle Cells in
Response to a Model Nitinol Stent Strut under Static Conditions In Vitro.

•

Aim 2: Investigation into the Effect of Nitinol Wire Corrosion on In Vitro VSMC
Response.

•

Aim 3: Evaluation of Phenotypic Behavior of Vascular Smooth Muscle Cells
Exposed to Concurrent Cyclic Strain and Flow Shear in Response to Model 316L
Stainless Steel and Nitinol Stent Struts.
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•

Aim 4: Analysis of HA Coated Nitinol Stent Struts and Their Subsequent Effect
on the In Vitro Phenotypic Behavior of Vascular Smooth Muscle Cells Exposed to
Cyclic Strain.

1.3 Summarized Project Aims
Aim 1: Computational Characterization of Simulator Contact Forces and Evaluation of
Synthetic Phenotypic Behavior of Vascular Smooth Muscle Cells in Response to a Model
Nitinol Stent Strut under Static Conditions In Vitro.
The present vascular simulator was designed to mimic the mechanical
environment of a stented artery after deployment of an intravascular stent. This is
accomplished by providing clinically significant levels of cyclical strain and flow shear,
as well as contact forces from the model stent strut on the adherent cultured cells. In this
initial study, characterization of this contact force is modeled to describe the mechanical
environment of the simulator in order to further our understanding of VSMC response to
mechanical stimulation. These forces are computationally simulated using ABAQUS
finite element analysis software. This data can be used to better understand observations
made as a result of strut contact on VSMCs.
This study proved to be useful as an initial proof of concept for the development
of our stented blood vessel model. In this study, it was shown that stimulating vascular
smooth muscle cells with a model stent strut composed of a round Nitinol wire under
static conditions stimulates a phenotypic shift towards a more synthetic phenotype. This
was shown through characterization of cell morphology and proliferation. The sample
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strut stimulus caused a morphological change in the VSMCs indicated by a decreased cell
aspect ratio. Additionally, analysis of cell enumeration showed a slight decrease in
VSMC enumeration at 24 hrs as compared to the control, which was presumably due to
destruction of the underlying cells by the wire. However, the analysis of DNA synthesis,
normalized to total protein content, demonstrated a significant increase in DNA synthesis
for the remaining cells in response to the model stent strut. This response was
investigated further by subjecting cells to preconditioned media, which was reserved
from the experimental groups and used to supplement cells not stimulated with a Nitinol
wire. This was done in order to determine if the cell response was due to exogenous
growth factors released by synthetic VSMCs; however, this was shown to have no
significant effect on VSMC proliferation. The cell response to the Nitinol wire was
evaluated further by repeating the experiments using a 48 hr time point, which yielded
similar results.

Aim 2: Investigation into the Effect of Nitinol Wire Corrosion on In Vitro VSMC
Response
The nickel-titanium alloy Nitinol has become an increasingly popular biomaterial
for use in vascular stenting due to its shape memory properties. However, its high nickel
content has been the cause for concern due to possible cell toxicity and alterations in
cellular activity. In the body, nickel ions can cause a number of different problems
including cancer, allergic reaction, and inflammatory response. [24-26] Additionally,
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recent studies have linked nickel allergies to increased restenosis in patients that received
nickel containing intravascular stents.[27, 28]
Traditionally, in vitro material biocompatibility studies involved evaluating cell
response where cells are cultured in the presence of a small sample of the material. In
this study, we present a slightly different approach to evaluate the biocompatibility of a
metallic biomaterial. Our study is based on estimating what local concentrations of
metallic ions are present at the site of implantation of a stent based on other studies in the
literature in order to establish a clinically significant concentration range for our cell
studies. We then quantified the concentrations of metallic ions present in conditioned
media in which Nitinol wires were allowed to corrode, and compared cell response to
actual ion concentration to provide better experimental reproducibility. This was
important to eliminate the variability of corrosion rates from metals (even from the same
lot) under similar conditions.
Cell culture experiments using vascular smooth muscle cells exposed to relevant
concentrations of nickel ions released from Nitinol showed two important responses.
First, a decrease in aspect ratio showing a morphological change possibly indicating a
shift towards a more synthetic phenotype has been observed. Secondly, a significant
decrease in α-actin expression was identified by immunostaining with a fluorescent tag.
At the highest concentration tested, average fluorescence decreased by approximately
26%, indicating a loss of the cellular contractile mechanism further supporting a change
in phenotype in response to the metallic ions. It is reasonable to suspect that this loss of
contractile marker smooth muscle α-actin combined with the decrease in aspect ratio
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indicates a synthetic phenotypic shift, which may contribute to the development of instent restenosis.

Aim 3: Evaluation of Phenotypic Behavior of Vascular Smooth Muscle Cells Exposed to
Concurrent Cyclic Strain and Flow Shear in Response to Model 316L Stainless Steel and
Nitinol Stent Struts.
Many studies have been published in the literature attempting to elucidate the role
of the stent’s material properties on restenosis. A major contribution to the minimization
of the risk of restenosis is attributed to the optimization of various stent design attributes.
One of the most important of these design criteria being evaluated is proper material
selection. The stent materials predominantly used clinically are 316L stainless steel and
Nitinol. Both of these materials are relatively biocompatible, and are generally selected
for the individual application whether it is more desirable to have a self-expanding or
balloon expanded stent. However, to date there are no studies readily available in the
literature comparing the effects of various metallic stent materials on smooth muscle cells
under dynamic culture conditions of concurrent cyclic strain and flow.
In the present study, we aimed at evaluating smooth muscle cell response to a
model stent strut while subjected to concurrent cyclic strain and fluid shear stimulation.
Results showed that under a dynamic culture environment, model stent implantation
resulted in a phenotypic shift toward a more synthetic phenotype marked by increased
DNA synthesis and decreased α-actin expression compared to the control. This is similar
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to the response expected in vivo. Additionally, the study shows that with regard to DNA
synthesis and expression of α-actin, Nitinol performs equally well to the traditionally
accepted gold-standard 316L stainless steel with no significant difference between the
two in any of the experiments carried out in this study.

Aim 4: Analysis of HA Coated Nitinol Stent Struts and Their Subsequent Effect on the In
Vitro Phenotypic Behavior of Vascular Smooth Muscle Cells Exposed to Cyclic Strain.
Hydroxyapatite (HA) has recently been proposed as a possible coating for
intravascular stents. It is beneficial because, in addition to promoting favorable cell
attachment, it may be used as a drug delivery platform. However, there is some concern
over the possible osteogenic potential of the material when implanted into an artery.
Additionally, little is known about the in vitro response of VSMCs to hydroxyapatitecoated biomaterials especially under dynamic culture conditions. This study utilized the
dynamic capability of our experimental setup by incorporating stimulation of VSMCs
using cyclic strain as well as the deployment of a model stent specimen. In this study,
stent strut geometry and material are held constant while surface coating is varied
between bare Nitinol and hydroxyapatite-coated Nitinol. This was done in order to
highlight the effect the material coating alone has on VSMCs while cultured under
clinically significant dynamic in vitro culture conditions. Cell phenotypic response was
evaluated by looking at DNA synthesis and α-actin expression. Additionally, in order to
evaluate the osteogenic potential of the HA coating, expression of alkaline phosphatase
(ALP), expression of osteopontin, and cellular calcification were analyzed. ALP and
12
	
  

osteopontin expression experiments were carried out under dynamic strain conditions in
the vascular simulator. However, in order to evaluate calcification of VSMCs over a
longer time period, a static study was conducted using HA coated 316L stainless steel
disks with calcium deposition evaluated at the end of the 10-day study.
The integrity of the HA coating itself was also evaluated in the present study.
This was done in two ways. First, the coating was analyzed using an electron dispersive
x-ray (EDS) method to insure that the surface was in fact coated with a thin layer of
hydroxyapatite. Secondly, the post strain integrity of the coating was evaluated by
straining the stent at levels representative of those expected upon deployment followed
by observation using scanning electron microscopy (SEM).
Results showed that VSMC DNA synthesis and α-actin expression was not
significantly different for the HA-coated Nitinol compared to the non-coated specimens.
The results indicated that HA-coated stents will likely be equally well accepted when
implanted in vivo compared to a bare Nitinol stent. Additionally, it was shown that while
alkaline phosphatase (ALP) expression was slightly elevated, cells showed no significant
calcification response to the HA coating and did not stain positive for osteopontin. This
indicated that any possible osteogenic response to the HA coating was quite minimal.
Additionally, EDS surface analysis studies demonstrated that the stent surface
was in fact coated with a thin layer of hydroxyapatite with a calcium/phosphorus ratio on
par with those observed by others in the literature for HA implants. Furthermore, SEM
analysis showed excellent post-strain integrity of the HA coating with minimal cracking
and/or flaking observed.
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-CHAPTER 2Aim 1: Computational Characterization of Simulator Contact Forces and Evaluation of
Synthetic Phenotypic Behavior of Vascular Smooth Muscle Cells in Response to a Model
Nitinol Stent Strut under Static Conditions In Vitro.

2.1 Introduction
The vascular simulator presently described was designed to mimic the mechanical
environment of a stented artery after deployment of an intravascular stent.[29] This was
accomplished by providing clinically significant levels of cyclical strain and flow shear
as well as contact forces from the model stent strut on the adherent cultured cells. In this
study, we aimed at quantifying this contact force to fully characterize the mechanical
environment of the simulator in order to further our understanding of VSMC response to
mechanical stimulation. In order to gain an accurate representation of the contact stress
profile, a computational model of the contact geometry was developed. In the stented
artery, cells are subjected to dynamic stimuli, such as concurrent cyclic strain and flow
shear. Additionally, the cells are also subjected to mechanical forces, such as the
outward radial force that is imparted upon the vessel wall by the implanted stent.
In the stented artery, the outward radial force of the stent upon the vessel wall is
vitally important. While it is important for the stent to provide mechanical forces to the
vessel wall to prevent elastic recoil and negative remodeling, outward stresses can be
high enough to cause significant trauma to the vessel wall leading to increased incidence
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of restenosis.[30-32] To date, there is a lack of in vitro data examining the effect of a
metallic indenter contacting the surface of a vessel wall. There is however, available data
evaluating similar conditions on articular cartilage and cartilage constructs.
Bae et al. evaluated the effect on chondrocyte viability following the stimulation
of human cartilage explants with bot spherical and flat-tipped indenters.[33] The
researchers showed that cell death was dependent on both indentation depth and number
of cycles. However, they also showed patterns of cell death dependent on areas of stress
concentrations caused by the indenter geometry. Spherical-tipped indenters caused
higher cell death at the center of the indenter where stress should have been the highest,
whereas flat-tipped indenters caused increased cell death at the edges of the indenter
indicative of the expected stress concentrations in this area.[33] Bae further confirmed
that these areas of increased cell death did experience elevated peak levels of strain of up
to approximately 5-30% which increased with increasing indentation displacement.[34]
Other research groups have investigated the response of chondrocytes to
compressive loading using a slightly different approach. Many groups have used
confined loading of cartilage constructs or explants in their models.[35-39] De Croos et
al. seeded porous calcium polyphosphate constructs with chondrocytes, which were then
over-laid with a layer of alginate, and subjected to cyclic compressive loading of an
estimated 1 kPa (1.4% strain) over 24 hours.[35] It was observed that after cyclic
compressive stimulation, the total collagen and proteoglycan production of the cells was
significantly increased when compared to static controls. These results are reinforced by
a similar experiment by Ragan et al. where chondrocytes cast in alginate disks were
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cyclically compressed resulting in similarly increased synthetic activity.[38] Davisson et
al. seeded chondrocytes onto porous poly-glycolic acid scaffolds and observed a similar
synthetic response to cyclic compressive loading.[39] Although the researchers did not
make an effort to judge cell proliferation of the samples, the increased synthetic activity
of the cells could potentially indicate and mitogenic response as well.
In this study, we hypothesized that the in vitro loading of vascular smooth muscle
cells with a model Nitinol stent strut would result in a synthetic response similar to that
observed in the literature for chondrocytes. This synthetic response was identified
through the evaluation of proliferation and DNA synthesis as well as changes in cell
morphology.

2.2 Materials and Methods
Contact Forces
Meshed Models
A geometric model was generated using the Catia v5 CAD program. This
geometric model was then imported into Hypermesh (Altair Inc.) for mesh generation.
The resulting mesh, as shown in Figure 2-1, was then imported into ABAQUS for
analysis. In our present model, continuum eight-node first-order reduced integration
hexahedron elements were used to mesh the silicone membrane sub-domain. The cell
layer and wire were meshed with tetrahedral elements. In order to ensure that the results
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obtained in the present study will not be changed significantly by further mesh
refinement, a mesh sensitivity analysis was carried out.

Figure 2-1: Hypermesh-Generated Mesh for FEM Analysis Using Both Hexahedral and
Tetrahedral Elements for the Silicone Membrane and Cell Layer/Wire Respectively
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Figure 2-2: Exploded Simplified Two-Dimensional Representation of Geometric Model
Computational Algorithm
It was not necessary to account for problems caused by excessive mesh distortions
due to the lack of very large strains and rotations in the model; therefore, the Lagrangian
formulation was used in order to solve the governing equations. Within the mesh, this is
tied to the material allowing the two to move and deform together.
In all cases, the transient non-linear dynamics calculations performed in the
present work were accomplished via general purpose FEA software ABAQUS/Explicit
[40]. Important relevant features of ABAQUS/Explicit were explained in further detail
in a recent work available in the literature [41]. Therefore, the remainder of this section
will provide only of brief general overview of this topic.
Initial Conditions
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All nodal velocities and element stresses and strains were set to zero at the
beginning of the simulation. In other words, at time t=0, the model was considered
quiescent and stress/strain free.
Boundary Conditions and Material Properties
In order to solve the model, a number of boundary conditions and assumptions
were made. First, the ends of the wire that are mounted with the wax were considered
fixed in space so that no displacement could occur. Additionally, the Lexan post
underneath the center of the silicone membrane was considered to be an infinite rigid
solid. Also, it was assumed that there was a “no slip” condition between the wire and the
cell layer or silicone membrane. The cell layer was also attached to the silicone
membrane such that no sliding could occur between the two layers. In order to reduce
the computational power required for the model, we took advantage of its two planes of
symmetry and only solved one quarter of the total model (Figure 2-6).
The wire, cells, and silicone were all assumed to be elastic. Material properties
for each part of the model are given in Table 2.1.
Table 2.1: Material Properties of FEA Model

Material	
  
Nitinol	
  Wire	
  
Cell	
  Layer	
  
Silicone	
  Layer	
  

Young’s	
  Modulus	
  (kPa)	
  

Poisson's	
  Ratio	
  

7.50E+07	
  

0.33	
  

0.1016	
  (diam)	
  

6.45E-‐06	
  

13.5	
  

0.46	
  

0.0025	
  

1E-‐06	
  

2.068E+04	
  

0.45	
  

0.381	
  

1.3E-‐06	
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Density	
  
3
Thickness	
  (mm)	
   (kg/mm )	
  

Contact Interactions
Contact surfaces between the wire and cell surface shared elemental nodes, which
thereby tied the two. The wire/contact surface normal interactions were analyzed in
ABAQUS/Explicit using a penalty- contact algorithm. Within this algorithm, (normal) a
set of linear springs served to resist contacting surface penetration, which thereby
produced proportionality between contact pressure and penetration depth. In general,
maximum default values were assigned to the (penalty) spring constants in order to
ensure computational stability during the simulation. Equilibrium of force collinear to a
direction normal to the contact-interface then caused the penetration to reach an
equilibrium value, which was contact-pressure dependent. It is important to note that
unless/until the “slave surface” nodes contacted/penetrated the “master surface” in the
model no contact pressures were developed. Additionally, there was no limit on the
magnitude of the contact pressure that could be developed.
Cell Culture
In this Institutional Animal Care and Use Committee (IACUC) approved study,
rat vascular smooth muscle cells (VSMC) were isolated from the aortas of SpragueDawley female rats between 6-10 weeks of age (Appendix C) and maintained with
Dulbecco’s Modification of Eagle Medium (DMEM) (Mediatech, Inc., 10-013-CV,
Herndon, VA) supplemented with 10% heat inactivated Fetal Bovine Serum (FBS)
(Sigma-Aldrich, F-4135, St. Louis, MO) and 1% Antibiotic-Antimycotic (Sigma-Aldrich,
A5955, St. Louis, MO). Experiments were carried out between passages 4-8. For
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experimental testing, cells were trypsinized using 0.25% Trypsin containing 0.2 mg/mL
EDTA (Sigma Chemical Company, E6511, St. Louis, MO).
Cell Seeding for Mechanical Testing
Silicone membranes were cut into circles 5.25 cm in diameter for each culture
plate out of biomedical grade silicone sheets (Lot SM04106803, Specialty
Manufacturing, Inc. Saginaw, MI, USA) 0.015" in thickness and 40 durometer Shore A.
The cut silicone sheets were then cleaned using sonication in deionized water and press
fit into the culture plates using an inner Lexan ring. The culture plates were then
autoclaved (Tuttnauer Brinkmann, 3870M, Jerusalem, Israel) at 121 degrees Celsius for
30 minutes and put into their appropriate place in the main body of the simulator. The
assembled system was then UV sterilized for 3 hours. To ensure the cells experience a
uniform stimulus, they were confined to the central post using a Teflon retainer ring 2.75
cm2 inner diameter and 1.75 cm in height. This ring was then removed prior to
mechanical testing. The Teflon rings were sonicated (Aquasonic Model P250T) in a 1%
detergent solution (Liquinox Critical Cleaning Detergent, Alconox, Jersey City, NJ,
USA) for 15 minutes followed by three rinses DI water. They were then autoclaved and
centered on the Lexan post on top of the silicone membrane. The area inside of the
Teflon rings was then coated with Type I Collagen (Purecol 3mg/ml, Advanced
Biomatrix, lot# 1356) diluted with sterile DI. The coated membranes were rinsed with
1.0 ml of Dulbecco’s Phosphate Buffered Saline (DPBS) (Media Tech, Inc., 21-031 CM,
Herndon, VA) before cell seeding. Cell counting was done using a hemocytometer
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(Hausser Scientific), and cells were seeded at a density of 5 x 104 cells, suspended in 1.5
ml culture media and incubated for 48 hours to allow the cells to attach.
Experimental Setup for Mechanical Testing
Immediately prior to mechanical testing, the DMEM containing FBS was
removed and the cells were rinsed briefly with phosphate-buffered saline (PBS). The
media was then replaced with a serum free media containing 1% antibiotic/antimycotic
for the duration of testing. Nitinol wires (ASTM F2063, Small Parts, part # NW-005-3605) 4.4 cm long and 0.127 mm in diameter were ultrasonically cleaned similarly to the
Teflon rings followed by EtO gas sterilization (AN 74i Anproline Gas Sterilizer,
Andersen Products Inc.) for 12 hours. The sterile wires were then carefully placed atop
the cultured cells and secured at the ends using molten Surgipath EM-400 paraffin wax
embedding medium (Surgipath Medical Industries Inc., Richmond, Illinois, USA) (Figure
2-3). The control groups also received the wax, but were not loaded with the wire. The
cells were then subjected to the wire loading stimulus for either 24 or 48 hours. Each
group contained three samples repeated in duplicate for a total of six samples. The
groups were a 24 hr control group (C24) (n=6), a 24 hr Nitinol wire loading group
(NW24) (n=6), a 48 hr control group (C48) (n=6), and a 48 hr Nitinol wire loading group
(NW48) (n=6).
Mechanical stimulation of cells was done using a vascular simulator previously
developed in our laboratory.[29] Briefly, the simulator is comprised of two simulator
bodies each having three independent channels such that six independent samples may be
cultured simultaneously. This dynamic simulator is capable of applying concurrent
22
	
  

cyclic strain and flow stimulation to cells through the use a computer controlled vacuum
pump as well as peristaltic pumps to provide a flow induced shear stimulus. However, in
the present study, cells were cultured inside the simulator under static conditions. The
apparatus previously described by Acampora et al. was slightly modified in order to
accept in order to accept a model vascular stent strut across the cell culture area, which is
secured in place using paraffin wax. [29]

Figure 2-3: Experimental Setup for Mechanical Testing Showing the Placement of the
Model Stent Strut
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Cell Morphological Analysis
Rhodamine-Phalloidin/DAPI
At the appropriate time point, the cells were removed from the incubator, fixed in
a 2% paraformaldehyde solution, and the cytoskeletal F-actin and cell nuclei were stained
using Rhodamine-Phalloidin (Invitrogen, R415) and by 4',6-diamidino-2-phenylindole
(DAPI) (Molecular Probes, D-1306, Eugene, OR) respectively. The cells were then
imaged using fluorescent microscopy (Nikon Inc., Diaphot 300, Melville, NY).
ImagePro Plus image analysis software (Media Cybernetics, Inc., Version 5.1, Silver
Spring, MD) was then used to take cell measurements including cell area, minor axis,
major axis, and aspect ratio.
Cell Proliferation
AQueous One Assay
At the appropriate time point (24 or 48 hrs), Cell Titer 96 AQueous ONE Solution
Cell Proliferation Assay (MTS) (Promega Corporation, G-3580, Madison, WI) was used
to evaluate cell proliferation. This was done by adding 1.25 ml of the AQueous One
assay solution to each plate and incubating for 3 hrs. After which, supernatant was
collected and 125 µl was dispensed into three wells of a 96 well plate for each of the
experimental plates such that each sample was repeated in triplicate. The absorbance was
then measured at 490 nm (Beckman Instruments, Inc., Model# DU 640B, Fullerton,
®

CA). Three wells containing DMEM with the assay solution added and not incubated
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with cells were used as controls to remove the background and obtain an adjusted
absorbance.
Evaluation of DNA synthesis
After mechanical stimulation, DNA synthesis was evaluated via an enzyme-linked
immunosorbent assay (ELISA) based bromodeoxyuridine (BrdU) incorporation assay
(Roche). Briefly, cells were BrdU labeled for a duration of 2 hours, after which they
were fixed in the provided fixation/DNA denaturation solution for 30 minutes.
Following this, the cells were incubated with an enzyme linked anti-BrdU antibody
solution for 90 minutes. After several rinses, the cells were then incubated with a
substrate solution for 30 minutes and absorbance was read in triplicate at 370 nm with a
reference wavelength of 492 nm. The remaining cells were then lysed using a 1% Triton
X-100 solution and the total protein content quantified via BCA assay in order to
normalize the absorbance values.
Conditioned Media
Conditioned media was reserved from one replication of both the 24hr and 48hr
studies. This media was then used supplement cells grown in 12-well plates with fresh
serum free DMEM serving as a control. Cells were seeded at a density of 6x104 cells per
well in DMEM containing 10% FBS and allowed 48 hrs to attach prior to the addition of
the conditioned media or control. Media from each sample was tested in duplicate such
that for the 24 hr NW experiments, the three samples gave rise to six conditioned media
samples. Cell proliferation was observed using AQueous One.
25
	
  

Statistical Analysis
All data was evaluated using an ANOVA statistical analysis paired with Tukey
analysis. This was done using SigmaStat statistical analysis software (Systat Software,
Inc., San Jose, CA) with p<0.05 indicating a significant difference.

2.3 Results
Computational analysis
The FEA software was used to gain an accurate representation of the contact
forces present in our vascular simulator. Figure 2-4 shows an isometric view of the
model taking advantage of two lines of symmetry for model simplification. In this figure,
the contacting wire is shown in green, the cell layer in red, and the silicone membrane in
yellow. Analysis of the model showed wire greatest displacement of the wire at the
edges as well as the center of the culture area in the negative z-direction. Because the
wire was fixed in space at both ends where no displacement could occur, this resulted in
greatest displacement of the wire into the cell and silicone layers at the edge of the
culture area. The resulting wire displacement profile is shown in Figure 2-5. Wire
displacement resulted in a S-like shape for the wire. Figure 2-6 shows the displacement
profile of the wire scaled 30,000x in order to further illustrate the s-shaped profile of wire
displacement. Furthermore, the strain displacement of the cell and underlying silicone
layer as a result of wire contact is shown in Figure 2-7. Maximum strain levels for the
cell and silicone layer in the model were estimated at approximately 1.065x10-5.
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The resulting von Mises and Principal stress profiles, shown in Figures 2-8 and 29 respectively, illustrate that stress followed the displacement profile with areas of
highest stress being at the edge of the culture area and the second highest being towards
the center of the culture area. Average principal stress at the center of the indenter
neglecting the edge effect was approximately 3.75x10-3 kPa across the culture area.
Additionally, the x-y plane stress profile demonstrated a stress profile that was dependent
on indenter geometry. Using the cylindrical indenter employed in the present study, this
resulted in maximum stress at the center of the indenter where displacement was the
greatest and decreasing at the indenter edges.

Figure 2-4: FEA Model Taking Advantage of Two Planes of Symmetry
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Figure 2-5: Displacement Profile of Nitinol Wire in FEA Model

Figure 2-6: Displacement Profile of Nitinol Wire Scaled 30,000x
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Figure 2-7: Strain Profile of Cell and Silicone Layer as a Result of Wire Displacement

Figure 2-8: Von Mises Stress Profile as a Result of Wire Contact
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Figure 2-9: Max Principal Stress Profile as a Result of Wire Contact

Static In Vitro Studies
Cell Morphological Analysis
The Rhodamine-Phalloidin stain was imaged and analyzed using ImagePro Plus
software. A statistical analysis showed a nearly identical aspect ratio (AR) for both the
24 and 48 hr control groups (C24 and C48). However, the experimental groups (NW24
and NW 48) demonstrated significantly decreased aspect ratios (P=<0.001 in both cases),
representing a reduction of approximately 29% and 19% respectively compared to the
controls shown in Figure 2-10. The aspect ratio was also shown to be significantly
different between NW24 and NW48 (P=<0.001).
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Figure 2-10: Comparison of Aspect Ratios Following the Application of a Model Nitinol
Stent Strut Vitro (* indicates a significant difference as compared to the control with P<
0.05)

Cell Proliferation
AQueous One Assay
Data analyzed from the 24 hr static study showed a significant decrease in cell
number compared to the control (P=0.012) (Figure 2-11). The 24 hr static group
demonstrated a cell number approximately 13% lower than that of the control.
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Figure 2-11: AQueous One Comparison of VSMC Enumeration Following the
Application of a Model Nitinol Stent Strut In Vitro (* indicates a significant difference as
compared to the control with P< 0.05)

BrdU assay
Data analyzed from the 24 hr BrdU assay, illustrated in Figure 2-12, showed a
significant increase in overall DNA synthesis for the NW group as compared to the
control group (P=0.045). The NW group showed an increase of approximately 76%.
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Figure 2-12: DNA Synthesis of VSMCs Following the Application of a Model Nitinol
Stent Strut In Vitro (* indicates a significant difference as compared to the control with
P< 0.05)

Conditioned Media
Cell Proliferation
There was no significant difference in VSMC proliferation in response to the 24
or 48 hr conditioned media as observed by AQueous One cell proliferation assay. This
suggested the difference in proliferation observed in the static study was likely due the
contact of the wire on the cell rather than exogenous growth factor production.
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2.4 Discussion
The FEA software was used to gain an accurate representation of the contact
forces present in our vascular simulator. This may be useful for possible future studies
utilizing different strut sizes in order to determine how VSMCs respond to varying
contact forces. Additionally, this data allows us to predict the fate of the VSMCs
immediately under the model stent strut that cannot be imaged. The maximum strain
values for the cell and silicone layers in the FEA model were calculated at approximately
1.065x10-5 as a result of the weight of the stent strut on the surface. This is far below the
value of approximately 0.54 shown in the literature to cause cell membrane rupture in
mouse myoblasts subjected to compressive loading in vitro.[42] These results suggest
that the strains encountered as a result of compressive loading from the weight of the
stent strut would not be high enough to rupture the underlying cells when implanted into
the in vitro model.
The present model was used to represent the contact condition of the model stent
strut across the culture area under fully static conditions. However, many dynamic
studies were conducted in aims 3 and 4, which utilized cyclic straining of the silicone
membrane by applying vacuum suction to stretch the membrane across the central Lexan
post. It is important to note that this linear stretching of the membrane across the post
would result in effectively “thinning” the membrane due to Poisson’s effect. This
thinning effect on the membrane would cause more of the weight of the wire to be born at
the ends fixed in space within the model. This would likely cause a slightly higher
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deformation of the wire combined with a slightly decreased strain on the cell and silicone
layers.
It is important to note that silicone membrane was coated with type I collagen
prior to cell seeding for in vitro studies; however, the collagen coating was not included
as a layer in the computational model. This may be one possible limitation of the current
model as the interlocking collagen fibers interwoven with the cultured cells would likely
lend structural rigidity to the layer giving it material properties closer to those of whole
tissue. However, the bulk properties of this extremely thin heterogeneous composite
layer would not be easily measured experimentally. For this reason, we utilized
previously published values for material properties of cultured cells for the FEA
model.[43]
Cell morphological analysis showed a significant decrease in cell AR for both the
24 and 48 hr wire contact groups as compared to their control. Additionally, results
showed a significant difference between the NW24 and NW48 groups. This data
suggested that the VSMC response with respect to aspect ratio was rapid within the first
24 hrs after which it began to return to a more normal state.
AQueous One analysis showed a decrease in overall cell number for the Nitinol
group compared to the control group. This decrease in cell number is likely due to a
mechanical destruction of the underlying cells as a direct result of scraping during the
placement of the wire across the culture surface. For this reason, the BrdU assay was
conducted in order to separate the rate of cellular proliferation from overall cell number.
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In contrast to results from the AQueous One assay which showed that overall cell
number decreases, the BrdU assay showed DNA synthesis of the remaining cells is
increased. This demonstrated that, while overall cell number was decreased due to
damaged caused by the placement of the wire, it lead to a very significant increase in
DNA synthesis of the remaining cells in response to the injury. This was somewhat
similar to the response observed in using in vivo models, which have routinely shown
increased neointimal thickness due to VSMC proliferation.[44-47]
Results from the present study indicate an increase in VSMC proliferation paired
with a simultaneous change in cell differentiation state. Traditionally, many studies
indicated a coupling of control mechanisms between regulation of cell proliferation and
differentiation making a cell incapable of doing both simultaneously.[48-51] It was
generally accepted that a cell must exit the mitogenic cycle to G1/G0 phase before a
change in differentiation state could occur. However, current research has demonstrated
that while these two events are at least somewhat independent allowing them to occur
simultaneously.[48] Studies which utilized myeloid cells have shown expression of
differentiation markers such as IL-8 and ICAM-1 coupled with simultaneous BrdU
incorporation.[52, 53] Furthermore, HL60 leukemia cells have been shown capable of
differentiation after being halted in various phases of the cell cycle.[48] These studies
demonstrate that DNA synthesis, as an indicator of proliferation, can occur in parallel
with differentiation. Additionally, cellular differentiation is independent of the phase of a
cell’s mitogenic cycle.
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2.5 Conclusion
Results from the present study demonstrated a slightly more complex than
expected contact condition between the cellular layer and the Nitinol wire indenter. The
displacement profile resulted in highest principal stresses at the edge and at the center of
the contact area in the y-z plane. Additionally, the cylindrical geometry resulted in
principal stresses highest in the center of the cylindrical indenter, where displacement is
greatest in the x-z place with stress magnitudes decreasing towards the indenter edge.
In vitro results from this proof-of-concept study showed an increase in DNA
synthesis as a result of Nitinol wire implantation compared to the control. This response
was paired with significant decrease in aspect ratio. Together, these results point toward
a phenotypic shift toward a more synthetic phenotype in response to implantation of a
model Nitinol stent strut, thus validating our present model. Furthermore, model strut
implantation resulted in a decrease in overall cell number as shown in results from the
AQueous One indicating that contact forces encountered upon wire implantation are
likely high enough to destroy underlying cells, however; this destruction of cells is likely
a result of elevated forces encountered at the moment of wire placement as forces
modeled from the weight of the wire itself were not shown to cause strains high enough
to cause rupture of cellular membranes. Additionally, results from conditioned media
studies showed conditioned media reserved from the static studies to have no effect when
subsequently added to VSMC static cultures. As such, the phenotypic shift was likely a
direct result of wire contact conditions rather than the release of exogenous growth
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factors. Overall, this study was successful at validating our model of a stented blood
vessel, making it a useful tool for further experimentation.
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-CHAPTER 3Aim 2: Investigation into the Effect of Nitinol Wire Corrosion on In Vitro VSMC
Response

3.1 Introduction
The nickel-titanium alloy Nitinol has become an increasingly popular biomaterial
for use in vascular stenting due to its shape memory properties. However, its high nickel
content has been the cause for concern due to possible cell toxicity and alterations in
cellular activity.
In the body, nickel ions can cause a number of different problems including
cancer, allergic reaction, and inflammatory response. [24-26] Additionally, recent studies
have linked nickel allergies to increased restenosis in patients that received nickel
containing intravascular stents.[27, 28] In an effort to understand these interactions
between the body and nickel-rich alloys, there have been many in vitro studies evaluating
the biocompatibility of Nitinol. Most of these studies evaluated biocompatibility of
Nitinol based upon observations such as cellular proliferation, apoptosis, and DNA
synthesis. However, more subtle changes such as altered protein expression are often
ignored. In many in vitro studies, cells are simply cultured in the presence of a small
sample of Ni/Ti alloy followed by the evaluation of cellular response. These studies pay
no attention to the inconsistency of corrosion rates and ion concentrations caused by
variations in surface area and material treatment.[54-57] Additionally, the majority of
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studies present in the literature do not utilize vascular smooth muscle cells (VSMCs). The
understanding of VSMC response following stent implantation is vitally important as it is
the synthetic response of VSMCs and subsequent proliferation and extracellular matrix
production that leads to the development of in-stent restenosis.[4]
VSMC response to Nitinol wire has been studied by Shih et al.[58] This group
utilized the accelerated electrochemical corrosion of Nitinol wire in growth media in
order to obtain test samples. This conditioned growth media was added to static cultures
of rat aortic VSMCs in order to demonstrate the toxicity of the corrosion byproducts on
cells, which was thought to be directly related to the nickel content. These experiments
showed a cytotoxic effect caused by the corrosion media that resulted in altered cell
morphology, [3H]-thymidine uptake ratio, and decreased cell number compared to the
control. These experiments employed relatively high nickel ion concentrations (up to
267 ppm). Growth inhibition was shown to be significant at a still relatively high nickel
concentration of 9 ppm and above.
Experiments that utilized corrosion of Nitinol wires in culture media without
applied voltage demonstrated much lower nickel concentrations. Rose et al. corroded
Nitinol in RPMI media with a ratio of 180 mm2 metallic surface per ml culture media for
72 hrs and measured a final nickel concentration of 0.02 ppm, which showed no
significant effect on L-929 mouse fibroblast proliferation.[59] Ryhanen et al. also showed
no decrease in cell proliferation caused by culturing human fibroblasts and osteoblasts in
the presence of Nitinol disks that led to nickel concentrations in the media of 8 and 5 ppb
respectively at 8 days as determined by flameless atomic absorption
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spectrophotometry.[60] Additionally, other studies have shown the addition of nickel
ions in concentrations of approximately 29 ppm induce an apoptotic response in human
bronchial epithelial cells in vitro. [61, 62] However, none of these studies involved
VSMCs in an attempt to look at the expression of contractile markers, such as smooth
muscle α-actin in response to varying concentrations of metallic ions present in the
culture media. This is of great importance as the proteome expressed by a cell is the most
telling indicator of cellular differentiation state. In the case of VSMCs, a decrease in
expression of contractile proteins is a primary concern in order to maintain normal
contractility.
Limited information is available in the literature about the nickel concentration
accumulated in vascular tissues immediately adjacent to an implanted Nitinol stent;
therefore, the clinical significance of the various ion concentrations used in the previous
studies is somewhat uncertain. However, the normal human serum concentration of Ni
can vary somewhat based on diet and other environmental factors but is approximately in
the range of 0.095-0.13 ppb [63-65]. The normal tissue concentrations of Ni are also
very low. In a recent study, Rahil-Khazen et al. analyzed human tissue samples from the
brain (front lobe and cerebellum), heart, kidney (cortex and medulla), liver, pancreas,
spleen, and ovary.[66] For all of the tissue samples analyzed, the Ni levels were found to
be below the instrument limit of detection of approximately 2.9 ppb.[66, 67] There has
been some research into ion concentrations resulting from various metallic implants other
than vascular stents. Two studies evaluating serum concentrations of various metallic
ions following the implantation of Co-Cr-Mo orthopedic implants found mean Ni serum
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concentrations of 0.7 ppb [68] and 0.4 ppb [69] respectively.[63] Another study by
Wataha et al. utilized a laser ablation technique combined with inductively coupled mass
spectroscopy (LA-ICPMS) to characterize tissue concentration of Ni ions at increasing
distances from subcutaneously implanted wire.[70] Pure nickel wire elicited an intense
inflammatory response compared to a polyethylene control implant and local tissue
necrosis up to 1mm from the wire with Ni concentrations as high as 48 ppm immediately
adjacent to the implant.[70] However, the Ni concentrations in the tissue fell off
exponentially 3-4 mm from the implants to below the 0.5 ppm limit of detection of the
method. This observation regarding high dependency of Ni concentration in tissue on
distance from the implant site is important because it could mean that SMCs immediately
adjacent to an implanted stent are experiencing levels of Ni ions much higher than
measured in serum or average tissue concentrations.
In the present study, we aimed at developing a clinically relevant in vitro model
useful to evaluate the response of VSMCs to varying low levels of Ni ions that should be
more representative of tissue concentrations found following the implantation of a
vascular stent. While we tested for more dramatic cell responses, such as altered
morphology and proliferation rate, we also evaluated the equally important expression of
the contractile marker smooth muscle cell α-actin. Additionally, the inconsistency of
metallic corrosion rates was eliminated by quantifying Ni concentrations prior to cell
culture experiments. This allowed cell response to be scaled with respect to the actual
concentration of Ni ions present rather than corrosion time.
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3.2 Materials and Methods
Nitinol wire specimens
Nitinol wires (ASTM F2063, Small Parts, part # NW-005-36-05) 4.4 cm long and
0.127 mm in diameter were ultrasonically cleaned and ethylene oxide sterilized (AN 74i,
Anprolene gas sterilizer, Andersen Products inc., Haw River, NC, USA) for 12 hours.
Two wires were then placed in 15 ml conical tubes with 10 ml serum-free Dulbecco’s
Modification of Eagle Medium (DMEM) (Mediatech, Inc., 10-013-CV, Herndon, VA,
USA) and allowed to corrode for varying time points. At the predetermined time point,
the media was removed from contact with the wire, and transferred to another sterile
15ml tube.
Quantification of Metallic Ions
Metallic ions present in the conditioned media were quantified using inductively
coupled plasma optical emission spectrometry (ICP-OES) (Ultima 2, Horiba JY,
Longjimeau, France). This is an analytical technique that is commonly employed to
detect trace metal concentrations. The instrument is equipped with a Meinhard
concentric glass nebulizer, a radial-view plasma, and a cyclonic spray chamber. The
Ultima 2 spectrometer consists of a 1.0 m Czerny-Turner monochromator equipped with
2400 grooves mm_1 holographic grating, controlled by JY Analyst v5.2 data acquisition
software.[71] Measurements were taken using a slight adaptation of a protocol
developed previously.[71] Briefly, nickel and titanium standards (High Purity Standards
100036-2 and 100062-2, Charleston, SC, USA) were used to construct a standard
43
	
  

calibration curve in DI water at two different wavelengths for each ion (Figure 3-1). This
was then used to construct a correlation plot of known vs. measured concentrations of
metallic ions in DMEM to validate the method, and in conjunction with the limit of
detection, determine the optimal wavelength to use for experimental measurements. The
correlation plots for the two optimal wavelengths are shown in Figure 3-2. Additionally,
the limits of detection for each metal over a concentration range of 0-0.3 ppm was
determined (LOD= 3σblank/ m where (σblank) represents the standard deviation of the blank
sample containing no metallic ion and (m) represents the slope of the calibration curve)
as shown in Tables 3.1 and 3.2.
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Figure 3-1: Standard Curves for Nickel and Titanium

Figure 3-2: Correlation Plots for Nickel and Titanium to Validate Method for Potential
Interference of Cell Media with Metal Signal
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Table 3.1: LOD for Nickel Ions
Nickel

221.647 nm

Concentration

SD

(ppm)

LOD (ppm)

341.467 nm

intensity

blank

intensity

blank

0

3652.12

104.99

12684.17

235.32

0.025

6594.76

206.22

16105.72

191.09

0.05

9846.93

166.3

18915.32

333.61

0.1

16599.51

973.19

25944.59

470.92

0.3

43937.16

883.32

52186.5

1891.2

0.00233061

0.00535634
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SD

Table 3.2: LOD for Titanium Ions
Titanium

323.452 nm

Concentration

SD

(ppm)

LOD (ppm)

334.941 nm

intensity

SD

blank

intensity

blank

0

1397.65

24.96

713.49

16.33

0.025

4582.61

95.46

1943.19

24.82

0.05

7815.27

9.88

3128.58

27.65

0.1 14262.21

111.18

5706.84

18.2

0.3 40941.32

417.49

16296.4

378.02

0.000567

0.00093941

Smooth Muscle Cell Culture
In this IACUC approved study, rat aortic smooth muscle cells were isolated from
Sprague-Dawley female rats between 6-10 weeks of age and maintained with Dulbecco’s
Modification of Eagle Medium (DMEM) (Mediatech, Inc., 10-013-CV, Herndon, VA)
supplemented with 10% heat inactivated Fetal Bovine Serum (FBS) (Sigma-Aldrich, F4135, St. Louis, MO) and 1% Antibiotic-Antimycotic (Sigma-Aldrich, A5955, St. Louis,
MO). Experiments were carried out using VSMCs between passages 4-8. For
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experimental testing, cells were trypsinized using 0.25% Trypsin containing 0.2 mg/mL
EDTA (Sigma Chemical Company, E6511, St. Louis, MO). Cell counting was done
using a hemocytometer (Hausser Scientific), and cells were seeded at a density of 2 x 104
cells into each well of a 24-well plate suspended in 1 ml culture media and incubated for
48 hours to allow the cells to attach.
Experimental Groups
This experiment was divided into 4 experimental groups of cells subjected to
various increasing concentrations of Ni ions. A group maintained in normal serum free
DMEM served as the control. The experimental groups corresponded to corrosion times
of 2, 10, 18, and 31 days. Each group including the control was repeated in triplicate.
Following the 48 hr attachment period, the culture media was removed from each well
and replaced with 1ml of either control serum free media or various corrosion
conditioned media samples. The cells were subjected to the test media solutions for a
duration of 48 hrs. Following the exposure time, the media was removed and the cells
evaluated using the test methods described in the following sections.
Cell Morphology
After the duration of conditioned media exposure, media was removed, and cells
were fixed in a 2% paraformaldehyde solution. The cytoskeletal F-actin and cell nuclei
were stained using Rhodamine-Phalloidin (Invitrogen, R415) and by 4',6-diamidino-2phenylindole (DAPI) (Molecular Probes, D-1306, Eugene, OR) respectively. The cells
were then imaged using fluorescent microscopy (Nikon Inc., Diaphot 300, Melville, NY).
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ImagePro Plus image analysis software (Media Cybernetics, Inc., Version 5.1, Silver
Spring, MD) was then used to measure the major and minor axes of the cells. The aspect
ratio was then calculated as the ratio of the major to minor axis lengths.
Cell Proliferation
At the appropriate time point, the conditioned media was removed and replaced
with fresh serum free DMEM containing Cell Titer 96 AQueous ONE Solution Cell
Proliferation Assay (MTS) (Promega Corporation, G-3580, Madison, WI) at a ratio of 5:1
and incubated for 3 hrs. After which, the solution was collected and 125 µl was
dispensed into three wells of a 96-well plate for triple replications of each experimental
group. The absorbance was then measured at 490 nm (Beckman Instruments, Inc.,
Model# DU 640B, Fullerton, CA) in order to evaluate the cell proliferative response.
®

Three wells containing DMEM with the assay solution added and not incubated with
cells were used as controls to remove the background and obtain an adjusted absorbance.
Expression of α-actin
Following the 48 hr duration of the corrosion media experiment, the media was
removed, and the cells were fixed in a 2% paraformaldehyde solution. The cells were
then covered with 1ml blocking solution (47ml PBS, 2g bovine serum albumin, 3ml
donkey serum, and 25µl Triton X) for 30 minutes at room temperature. They were then
treated with the primary mouse anti-α-actin antibody for 12 hrs at 4 °C followed by a 2hr
treatment with donkey anti-mouse secondary antibody. The cells were then stained using
4',6-diamidino-2-phenylindole (DAPI) to assist in distinguishing individual cells after
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imaging. Imaging was done using fluorescent microscopy (Nikon Inc., Diaphot 300,
Melville, NY). ImagePro Plus image analysis software (Media Cybernetics, Inc., Version
5.1, Silver Spring, MD) was used to measure the green densitometry of the stained cells.
Statistical Analysis
Data was evaluated using an ANOVA statistical analysis paired with Tukey
analysis. This was done using SigmaStat statistical analysis software (Systat Software,
Inc., San Jose, CA) with p<0.05 indicating a significant difference.

3.3 Results
Quantification of metal ions released
For the determination of metallic ion released from Nitinol into DMEM, 11
different samples ranging in corrosion time from 24 hrs to 31 days were utilized. The
instrument was calibrated such that the control media where no additional nickel was
added was set as the standard zero point. In actuality, the blank media contained Ni
concentrations of approximately 1.1 ppb. The standardized measured ion concentrations
are given shown in Figure 3-3.
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Figure 3-3: Nickel Concentrations Released from Nitinol Wire with Respect to Time

Cell morphology
Cell morphology was evaluated by the measurement of cell aspect ratio (major
axis/minor axis). Higher aspect ratios are known to be one indication of a more
contractile phenotype in smooth muscle cells.[72] There was a significant difference in
aspect ratio in all of the groups as compared to the control, which can be seen in Figure
3-4 (P=<0.001). However, a significant difference was not observed amongst the
different experimental groups in response to increasing ionic concentrations. At the
highest Ni concentration tested, the mean aspect ratio was decreased by approximately
25% compared to the control.
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Figure 3-4: Cell Aspect Ratio vs. Nickel Concentration

Cell proliferation
There was no significant difference in cellular proliferation in response to any of
the nickel ion concentrations employed in the present study as evaluated using the
Aqueous One cell proliferation assay. This can be clearly observed in Figure 3-5
(P=0.228).
Expression of α-actin
Interestingly, the most significant difference observed in cell response was with
respect to the expression of α-actin (P=<0.001). This is clearly illustrated in Figure 3-6.
A significant difference in fluorescence compared to the control was observed at all but
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the lowest concentration of Ni ions tested in this study. At the highest concentration
tested, a 26% decrease in fluorescence intensity was observed as compared to the control.

Figure 3-5: Results of AQueous One Cell Proliferation Assay

Figure 3-6: Fluorescence Intensity of Immunostained α-Actin vs. Nickel Concentration
53
	
  

3.4 Discussion
Metal Ion Quantification
Results from the metal ion quantification demonstrated a high variability of Ni
release over time from the various wire samples. This differential Ni ion release points to
the aforementioned lack of predictability and exact reproducibility of experimental
conditions from simply culturing cells in the presence of a sample of a metallic
biomaterial. Furthermore, no measurable concentrations of Ti ions were observed in any
of the samples. This is presumably due to the high reactivity of Ti ions. Any Ti ions
released from the Nitinol wire would have immediately reacted with oxygen forming
titanium oxide or dioxide and precipitated out of solution and thus not been measured by
the ICP-OES analysis.
Cell Morphological Analysis
Cell morphological analysis demonstrated a significant decrease in cell aspect
ratio in response to nickel ions present in conditioned media samples. However, there
was no significant difference observed amongst the different experimental groups in
response to increasing nickel ion concentrations. This was presumably due to the
relatively low ion concentrations employed in this experiment. At higher Ni
concentrations, greater morphological changes would likely be observed due to ion
toxicity.
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Cellular Proliferation
No significant difference in cell proliferation was observed for any of the nickel
ion concentrations employed in the present study. Similar to the results from the
evaluation of cell morphology, the lack of observed differences in cellular proliferation
was likely the result of the low ion concentrations employed in these experiments. It is
common knowledge that very high nickel concentrations are toxic. The toxicity
threshold for VSMCs at which proliferation starts to become significantly inhibited was
demonstrated by Shih and collaborates to be approximately 9ppm in vitro.[58] It was not
our intention in these experiments to observe cellular changes under extreme conditions
that would likely never be encountered in vivo. Implanted Nitinol stents are not known to
cause excessive levels of local tissue necrosis indicating that they likely do not cause high
levels of cellular death as a direct result of metallic ion release.
α-Actin Expression
The most prominent response observed in this study was a steady decrease in αactin expression in response to increasing nickel ion concentration. The decrease in αactin expression indicates a progressive loss of the contractile mechanism present in the
cell resulting in a decrease in the contractile ability of the cell and subsequently result in a
lack of muscular tone in the vessel wall. The lack of muscular tone in the vessel wall
would lead to an increase in vessel wall strains. This is of a great importance because
increasing mechanical strain has been linked to increased proliferation of VSMCs in vitro
[73-77]. Furthermore, high blood pressure, and thus increased force on the vessel wall,
and increased strain by as much as 15%, causes thickening of the blood vessel wall due in
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part to VSMC proliferation in vivo.[76, 78-80] It is reasonable to expect that increased
strains as a result of loss of VSMC contractility would cause a similar adaptive
thickening in a stented artery thereby contributing to the development of restenosis. It is
also plausible to assume that the trend of decreasing α-actin expression, as indicated by
fluorescence intensity, would continue with increasing ionic concentrations below those
concentrations shown to affect cell proliferation in vitro previously mentioned in the
introduction by Shih and others further reducing VSMC contractility.
Possible mechanisms of action Nickel Ions on Eukaryotic cells
In this study, we have shown increasing concentrations of nickel ions in culture
media to affect VSMC morphology and expression of α-actin. While our study showed
no effect on cell proliferation, other studies available in the literature demonstrated that
nickel concentrations higher than those we employed do significantly affect cell
proliferation. The questions that immediately arise from these observations are how and
why do nickel ions have this effect on eukaryotic cells? While the exact mechanism by
which nickel ions affect various aspect of cell metabolism remains somewhat unclear,
several studies available in the literature may help to shed some light on the matter. One
early study by Webb et al. looked at the in vitro distribution of nickel ions in the various
subcellular fractions of mouse dermal fibroblasts following the addition of nickel
chloride.[81] It was shown that highest nickel concentrations in the cell in decreasing
order were in the cell nuclei, cell sap, mitochondria, and microsomes.[81] Within the cell
nuclei, the majority of the nickel was recovered in the nucleoli. This result agrees with
previous data gathered from a study by Heath et al. in which tumors were induced in rats
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by injection of metallic nickel powder in suspension.[82] Analysis of tissue samples
from these tumors demonstrated nickel content to be highest in the nuclear fraction
followed by the mitochondrial and microsomal fractions in decreasing order.[82]
From these studies, it is reasonable to speculate that increasing concentrations of
nickel ions would first affect ribosomal RNA transcription by accumulating in the
nucleolus. As nickel concentrations increased, it would likely then lead to an increased
inhibition of RNA transcription as well as inhibitory concentrations in the mitochondria
affecting ATP synthesis. This assumption would follow with the observations of nickel
ions first affecting protein expression, which increases with increasing nickel
concentration followed by inhibition of cellular proliferation as the concentration
increases further eventually causing cell death.
Additionally, the observed decrease in aspect ratio could be explained by several
studies available in the literature that evaluated the effect of nickel ions on the F-actin
and microtubules. A study by DalleDonne et al. demonstrated that the addition of nickel
to the polymerization of actin and tubulin monomers in solution results in the formation
of shorter polymers compared to the control.[83] Additionally, the Ni induced actin
filaments were prone to aggregating in groups of twos and threes. Li et al. demonstrated
significant change in cytoskeletal morphology marked by the aggregation of microtubules
in 3T3 cells in response in 2mM concentrations of NiCl2 for 20 hrs in vitro compared to a
control.[84] Furthermore, Gunaratnam et al. observed decreased F-actin expression in
combination with what was thought to be condensation of the F-actin filaments in
response to exposure of rat hepatocytes to 500µM concentrations of Ni ions compared to
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a control.[85] The disruption to the normal cytoskeleton cited in the aforementioned
studies is a possible cause of the decrease in aspect ratio observed in the present
experiment.
The exact mechanism by which Ni ions elicit various observed cellular responses
has not been completely elucidated. However, it is thought to be linked to an ability of
Ni ions to compete with Mg ions at various binding sites as well as affect various calcium
ion channels.[86, 87] Several studies have shown that increasing the extracellular Mg
concentration blocks the various effects of Ni ions on cells in vitro including damage to
and polymerization inhibition of DNA as well as inhibition of cell proliferation.[88-90]
Furthermore, Mlinar et al. demonstrated the ability of Ni ions to block T-type voltage
gated calcium channels in rat and human C cell lines in a concentration dependent
manner.[91] This effect was not inhibited by increasing the extracellular calcium
concentration. The channel block was hypothesized to be due to occlusion of the channel
pore by the metal ion by binding to a calcium binding site outside of the membrane
electric field.[91]

3.5 Conclusion
In this study, a lack of predictability of corrosion rates and subsequent ion release
even amongst metallic samples from the same lot held under the same conditions was
demonstrated. This variability of experimental conditions was eliminated by using ICPOES to quantify the concentrations of Ni present in our experimental media. This allows
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the experimental conditions to be predictably reproduced in future studies in order to
evaluate other aspects of cellular response.
As shown by others [59, 60], no change in cellular proliferation was observed at
the low nickel ion concentrations employed in this study. However, the studies present in
the literature that did show a significant difference in various indicators of cellular
proliferation [58, 61, 62] employed relatively high Ni concentrations that would be
unlikely to occur in vivo as a direct result of an implanted medical device. This is
especially true for an intravascular stent where such a small amount of biomaterial is
present in the tissue. The present study utilized much lower ionic concentrations in an
effort to evaluate the more subtle effects that such low concentrations have on cell
response that would be more likely to carry over into clinical observations. Our results
have shown altered cell morphology as well as a decreased smooth muscle cell α-actin
expression in response to low nickel concentrations in vitro. These observations shed
some light on one possible contributing factor to the development of in-stent restenosis.
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-CHAPTER 4Aim 3: Evaluation of Phenotypic Behavior of Vascular Smooth Muscle Cells Exposed to
Concurrent Cyclic Strain and Flow Shear in Response to Model 316L Stainless Steel and
Nitinol Stent Struts.

4.1 Introduction
Many studies have been published in the literature attempting to elucidate the role
of the stent, as well as its properties, on restenosis. A major contribution to the
minimization of the risk of restenosis lies in the optimization of various stent design
attributes. One of these design criteria that will be evaluated in this study is material
selection. Table 4.1 lists the most important properties of a biomaterial surface that affect
its interactions with proteins and subsequent thrombogenicity (Dee et al) emphasizing
material composition as a major determining factor. The predominant stent materials used
today are 316L SS and Nitinol. Both of these materials are relatively biocompatible, and
they are generally selected for the individual application whether it is more desirable to
have a self-expanding or balloon expanded stent. However, there are few studies
available in the literature comparing the effects of various metallic stent materials on
smooth muscle cells under dynamic culture conditions.
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Table 4.1: Properties of Surfaces that Affect Their Interaction With Proteins [13]
Feature

Effect

Topography

Greater texture exposes more surface
area for interaction with proteins

Composition

Chemical makeup of a surface will
determine the types of intermolecular
forces governing interaction with
proteins

Hydrophobicity/ Free Surface Energy

Hydrophobic surfaces tend to bind more
protein

Heterogeneity

Non-uniformity of surface characteristics
results in domains that can interact
differently with proteins

Electrical Potential

Surface potential will influence the
distribution of ions in solution and
interaction with proteins

As a metallic surface is exposed to air, a certain degree of oxidation takes place.
For example, stainless steel and chromium based alloys form a surface layer composed
primarily of hydroxide or chromium oxide, whereas titanium readily oxidizes on its
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surface to form the quite stable titanium dioxide.[92] The stability of these ceramic
oxidized layers is taken advantage of by using a process called passivation as a surface
treatment method for metallic implants.[93] Passivation is performed to further enhance
the surface stability following electropolishing in order to form a thicker stable oxide
layer on the surface. In this process, stainless steel stents are rinsed with deionized water
following electropolishing and then soaked in a nitric acid and sodium dichromate
solution to form a stable chromium dioxide layer on the stent surface.[94] This
passivation step is generally not needed for titanium alloy stents, as they readily oxidize
to form a titanium oxide rich layer under atmospheric conditions.[94] In addition to
enhancing the surface characteristics of an implant, the formation of an oxide layer on the
material surface has also been shown to help “seal” the implant and reduce the release of
metal ions in the body.[93, 95, 96] This may be of particular interest in dealing with the
high levels of nickel contained in the alloy Nitinol.
The corrosion byproducts of both stainless steel and Nitinol have been shown by
Shih et al. to inhibit VSMC growth at high concentrations in static culture.[58, 97]
However, the afore mentioned studies utilized electrochemical corrosion of sample wires
to obtain concentrations of corrosion products that are much higher than those that would
be expected in vivo. Additionally, experimentation was done under static conditions,
which may not be representative of the cellular response in a dynamic culture
environment. Other experiments have compared the static corrosion byproducts of
Nitinol and stainless steel. Ryhanan et al. immersed samples of Nitinol and stainless steel
in DMEM and observed an initially higher release of Ni ions from the Nitinol sample, as
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determined by flameless atomic adsorption spectrophotometry, compared to the stainless
steel sample.[60] However, the concentrations leveled out after approximately two days
and remained so until the 10 day final time point. Furthermore, stainless steel contains
small amounts of chromium that could be released into the culture media. Chromium has
been shown to lead to DNA damage, cellular apoptosis, and carcinogenesis.[98-100]
The purpose of this study is to evaluate smooth muscle cell response to a model
stent strut while subjected to concurrent cyclic strain and flow shear mechanical
stimulation. This model is used to elucidate any variable response of the cells due to
variations in strut material while holding all other variables constant.

4.2 Materials and Methods
Cell Culture
In this IACUC approved study, rat vascular smooth muscle cells (VSMC) were
isolated from the aortas of Sprague-Dawley female rats between 6-10 weeks of age
(Appendix C) and maintained with Dulbecco’s Modification of Eagle Medium (DMEM)
(Mediatech, Inc., 10-013-CV, Herndon, VA) supplemented with 10% heat inactivated
Fetal Bovine Serum (FBS) (Sigma-Aldrich, F-4135, St. Louis, MO) and 1% AntibioticAntimycotic (Sigma-Aldrich, A5955, St. Louis, MO). Experiments were carried out
between passages 5 to 8. For experimental testing, cells were trypsinized using 0.25%
Trypsin containing 0.2 mg/mL EDTA (Sigma Chemical Company, E6511, St. Louis,
MO).
63
	
  

Cell Seeding for Mechanical Testing
Silicone membranes were cut into circles 5.25 cm in diameter for each culture
plate out of biomedical grade silicone sheets (Lot SM04106803, Specialty
Manufacturing, Inc. Saginaw, MI) 0.015" in thickness and 40 durometer Shore A. The
cut silicone sheets were then cleaned using sonication in deionized water and press fit
into the culture plates using an inner Lexan ring. The culture plates were then autoclaved
(Tuttnauer Brinkmann, 3870M, Jerusalem, Israel) at 121 °C for 30 minutes and put into
their appropriate place in the main body of the simulator. The assembled system was
then UV sterilized for 3 hours. The Teflon rings were sonicated in a 1% detergent
solution (Liquinox Critical Cleaning Detergent, Alconox, Jersey City, NJ) for 15 minutes
followed by three rinses DI water. They were then autoclaved and centered on the Lexan
post on top of the silicone membrane. The area inside of the Teflon rings was then
coated with Type I Collagen (Purecol 3mg/ml, Advanced Biomatrix, lot# 1356) diluted
with sterile DI. This resulted in a collagen coated culture area contained to the top of the
simulator post such that the cultured cells experienced equibiaxial strain stimulation. The
coated membranes were rinsed with 1.0 ml of Dulbecco’s Phosphate Buffered Saline
(DPBS) (Media Tech, Inc., 21-031 CM, Herndon, VA) before cell seeding. Cell counting
was done using a hemocytometer (Hausser Scientific), and cells were seeded at a density
of 6 x 104 cells per plate, suspended in 1.5 ml culture media, and incubated for 48 hours
to allow the cells to attach.
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Experimental Setup for Mechanical Testing
Nitinol wires (ASTM F2063, Small Parts, part # NW-005-36-05) and 316L
stainless steel wires (ASTM F138, Small Parts, part # GWXX-0050-60-05) 4.4 cm long
and 0.203 mm (0.008 inches) in diameter were ultrasonically cleaned similarly to the
Teflon rings followed by EtO gas sterilization (AN 74i Anproline Gas Sterilizer,
Andersen Products Inc.) for 12 hours. The sterile wires were then carefully placed atop
the cultured cells and secured at the ends using molten Surgipath EM-400 paraffin wax
embedding medium (Surgipath Medical Industries Inc., Richmond, Illinois, USA). The
control groups also received the wax, but were not loaded with the wire. The cells were
then subjected to the wire loading combined with concurrent cyclic strain and flow shear
stimulation for 24 hours. The study consists of four groups each containing three
samples. The groups were a Nitinol wire group (NiTi), a stainless steel wire group (SS),
a sham injury group (Sham), and a control group (Ctrl) containing no wire. For the sham
injury group, a Nitinol wire was placed for approximately 5 seconds and removed in an
attempt to separate the effect of strut contact from that of cell injury or death as a result of
wire placement.
The vascular simulator described presently is comprised of two simulator bodies
each having three independent channels (Figure 4-1).[29] This thereby allows for six
different samples, each independent from one another. Equibiaxial strain was applied to
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cells cultured on the silicone membrane by applying vacuum suction in order to stretch
the membrane over the central post at a rate of 1 Hz. To ensure the cells experienced a
uniform strain stimulus, they were confined to the central post region using a Teflon
retainer ring of 2.75 cm2 inner diameter and 1.75 cm in height. This ring was then
removed prior to mechanical testing. Additionally, silicone lubricant was applied atop
the Lexan post in order to reduce friction between the membrane and post. The strain
was controlled at 5% by regulating cyclic vacuum pressure using Flexcell 3000 system.
A peristaltic pump was employed in order to provide a flow rate of 400 ml/min across the
culture area. This was previously calculated to result in a low level of wall shear stress of
approximately 0.3 dynes/cm2 in order to promote cell proliferation.[29, 101] The
experimental setup is shown in Figure 4-1. A variety of design parameters such as
entrance length, channel depth, and channel width were carefully selected in order to
mimic various physiological flow conditions including laminar flow, fully developed
flow at the cells, and desired levels of shear stresses. These parameters were confirmed
by calculating the Reynold’s number for the channel flow.[102]
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Figure 4-1: Dynamic Vascular Simulator Setup

Evaluation of DNA Synthesis
After mechanical stimulation, DNA synthesis was evaluated via an ELISA based
bromodeoxyuridine (BrdU) incorporation assay (Roche). Briefly, cells were BrdU
labeled for a duration of 2 hours after which they were fixed in the provided
fixation/DNA denaturation solution for 30 minutes. Following this step, the cells were
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incubated with an enzyme linked anti-BrdU antibody solution for 90 minutes. After
several rinses, the cells were then incubated with a substrate solution for 30 minutes and
absorbance was read at 370 nm with a reference wavelength of 492 nm. The remaining
cells on the culture plate were then lysed using a 1% Triton X-100 solution and the total
protein content quantified via BCA assay in order to normalize the absorbance values.
Expression of α-Actin
The expression of α-actin was measured using a slight modification of an
established ELISA assay (Appendix D).[103] Briefly, the cells were PBS rinsed and
fixed in a 2% paraformaldehyde solution. The cells were then covered with 1ml blocking
solution (47ml PBS, 2g bovine serum albumin, 3ml FBS, and 25µl Triton X-100) for 45
minutes at room temperature. They were then treated with the primary mouse anti-αactin antibody diluted 1:200 for 2 hrs at RT, followed by a 2 hr treatment with a
biotinylated mouse IgG secondary antibody diluted 1:200. The cells were then incubated
for 45 minutes at 37 °C with a streptavidin conjugated alkaline phosphatase diluted 1:500
in TBST buffer (pH 8). Finally, the cells were incubated with the subtrate solution (3mM
pNpp, 0.05 M Na2CO3, 0.05 mM MgCl2) for 45 minutes at 37 °C, and the absorbance
read at 405 nm. The cells were then lysed using a 1% Triton X-100 solution and total
protein measured using BCA in order to normalize the absorbance values to total protein
content.
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Statistical Analysis
All data was evaluated using an ANOVA statistical analysis paired with Tukey
analysis. This was done using SigmaStat statistical analysis software (Systat Software,
Inc., San Jose, CA) with p<0.05 indicating a significant difference.
4.3 Results
DNA Synthesis
DNA synthesis was used as a tool to evaluate cell proliferation. Data showed
both SS (P=0.026) and Nitinol (P=0.002) stent struts demonstrated a significant increase
in DNA synthesis as compared to the control. However, there was not a significant
difference between the SS and Nitinol groups (P=0.274). Additionally, there was no
significant difference between the control and sham groups (P=0.585). Both 316L
stainless steel and Nitinol yielded significantly increased absorbance of approximately
81% and 125% respectively over the control group. However, the sham group was not
significantly different to the control with absorbance values returning to within
approximately 29% of the control group in the 24hr time point tested.
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Figure 4-2: BrdU Assay of VSMCs Subjected to Concurrent Cyclic Strain and Fluid
Shear (* indicates a significant difference as compared to the control with P< 0.05)

Expression of α-Actin
There was a significant decrease in α-actin expression in the SS (P=0.012), NiTi
(P=0.002), and Sham (P=0.042) groups as compared to the control; however, no
significant difference was observed with Nitinol compared to 316L stainless steel or
either group compared to the sham group. This resulted in an approximately 42%, 55%,
and 32% decrease in absorbance for the SS, NiTi, and Sham groups respectively as
compared to the control.
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Figure 4-3: α-Actin ELISA Assay of VSMCs Exposed to Concurrent Cyclic Strain and
Flow Shear (* indicates a significant difference as compared to the control with P< 0.05)

4.4 Discussion
DNA synthesis
BrdU analysis showed a decrease in DNA synthesis for both the SS and NiTi
groups as compared to the control; however, no significant difference was observed
between the two. This indicated that with respect to cell proliferation, as illustrated
through the evaluation of DNA synthesis, there was not significant difference regarding
the effect of stent strut composition between 316L stainless steel and Nitinol.
Additionally, it appeared that the observed response of increased DNA synthesis caused
by stent strut contact with the smooth muscle cells was a rapidly reversible one further
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indicated by the lack of difference between the control and sham groups after a time
period of 24 hours.
Expression of α-Actin
Results demonstrated a significant decrease in α-actin expression in all of the
experimental groups as compared to the control; however, no significant difference was
observed between the SS and NiTi groups. This response indicated that the loss of αactin expression was a rapid event that likely occurs in response to injury incurred upon
placement of the model stent strut. Similar to results observed from DNA synthesis, the
decreased α-actin expression appeared to be independent of stent material composition
between 316L stainless steel and Nitinol. However, contrary to results observed for
DNA synthesis, the sham group demonstrated that the decrease in α-actin expression was
a somewhat lasting response that was not reversible after removal of the strut within the
24 hr time period tested.
It is important to note that the higher modulus of elasticity of 316L stainless steel
employed in this study would result in less wire deformation causing slightly lower
strains across the culture area as compared to the Nitinol strut as modeled in Aim 1.
However, results showed that these slightly lower strains did not noticeably affect cell
proliferation or α-actin expression in the present study. Additionally, while the
chromium content of SS was of some concern because of potential to lead to DNA
damage and apoptosis[98-100], no noticeable effect was observed in DNA synthesis.
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4.5 Conclusion
The placement of a model stent strut under dynamic conditions of 5% cyclic
strain and a 400 ml/min flow rate giving rise to a shear of 0.3 dynes/cm2 were shown to
lead to increased DNA synthesis and decreased α-actin expression indicating a possible
shift toward a synthetic phenotype. These results were somewhat expected and are quite
representative of what occurs post implantation in an in vivo model. While the sham
groups did demonstrate differences in the possible reversibility of these responses within
24 hrs of the removal of the contact stimulus, there was no observed difference between
the two materials tested in all assays in response to model strut contact. This illustrated
that with respect to its propensity to influence a synthetic phenotypic shift in VSMCs
cultured under dynamic culture conditions, Nitinol appears to be equally suited for use as
compared to the traditionally accepted gold standard of 316L stainless steel.
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-CHAPTER 5Aim 4: Analysis of HA Coated Nitinol Stent Struts and Their Subsequent Effect on the In
Vitro Phenotypic Behavior of Vascular Smooth Muscle Cells.

5.1 Introduction
Many studies have been published in the literature attempting to elucidate the role
of the stent itself, as well as its material and physical properties, on restenosis. In the
present study, we used our model to elucidate the response of vascular smooth muscle
cells due solely to surface coating. Surface coatings can be beneficial in several ways.
First, coatings can be loaded with anti-proliferative and/or anti-coagulant drugs to help
reduce thrombosis and restenosis as is done with drug eluting stents (DESs) currently on
the market. Additionally, surface coatings are beneficial to provide a more favorable
blood-biomaterial interface as well as prevent possible structural weakening of the stent
itself.[104]
Polymeric Surface Coatings
Much of the early work on stent surface coating focused on the use of applied
polymeric coatings in order to minimize the body’s response to the implanted
biomaterial. Researchers sought to develop an optimal surface for tissue contact that
would elicit a minimal inflammatory and likewise proliferative response. Porcine models
have also shown coatings such as PLL-g-PEG to be effective at reducing both thrombosis
and restenosis.[105] It is important to note that not all polymer coatings tested have been
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shown to reduce thrombosis, inflammatory response, and subsequent restenosis compared
to a bare metal stent.[105, 106] In fact, many of the early polymers tested caused an
intense inflammatory response.[107] Some other polymers that have been the recent
subject of experimental testing include among others: poly(styrene-b-isobutylene-bstyrene) trade name Translute [108], ethylene-vinyl acetate (EVA) [109], ethoxyethyl
methacrylate-based copolymers by Medtronic [110], polyethylene-co-vinyl acetate
(PEVA), phosphorylcholine [111], and poly n-butyl methacrylate (PBMA)
copolymer[112]. It has also been shown that similar polymers of slightly different
formulations can cause very different reactions in vivo.[106, 113] This was well
illustrated by the porcine model of Lincoff et al.[113] This experimental study showed a
marked difference in the inflammatory response following implantation of stents coated
with an absorbable coating of poly-L-lactic acid (PLLA). The low molecular weight
formulation of the polymer triggered an intense local inflammatory response, whereas the
high molecular weight formulation was seemingly well tolerated by the animals in the
experimental group.[113]
Another issue for concern with the use of polymer coated stents is the long term
stability of the polymer coating.[107] The long term exposure of polymers to the harsh
hemodynamic and chemical environment inside the body may lead to their eventual
degradation, resulting in the possible release of both toxic byproducts and polymer
fragments causing cell death as well as late inflammation and thrombosis.

75
	
  

Ceramic Surface Coatings
A number of different ceramic coatings have been investigated for their use with
intravascular stents. The use of silicon carbide coatings has been shown to reduce stent
thrombogenicity at 90 min in the carotid artery of a porcine model compared to an
uncoated control.[114] This reduction in thrombus formation could possibly result in a
reduced inflammatory response and subsequently reduced SMC proliferative response.[4,
13] However, the TENISS clinical trial comparing silicon carbide coated stents to
uncoated stents showed no significant difference between the two in clinical and
angiographic restenosis rates in humans at approximately 4.7 +/- 1.2 months [115], which
again held true at approximately 81 +/- 12 weeks follow-up [116].
Another form of ceramic surface coating currently being studied is hydroxyapatite
(HA, Ca10(PO4)6(OH)2).[117] HA coating of stents is a relatively new idea, but may be
beneficial for several reasons. First, HA forms a porous coating on the stent surface that
can be utilized at a drug delivery platform that does not elicit the same degree of
inflammatory response associated with polymeric delivery systems.[118-121]
Additionally, HA coated implants including nickel-titanium alloys and stainless steel
have shown a reduced release of metallic ions including nickel as compared to a noncoated control in vitro.[122-124] HA is also a very biocompatible material that promotes
cell attachment; however, its osteogenic potential may be the cause for some concern.
Nadra et al. showed that HA crystals were shown to promote TNF-α (a pro-inflammatory
cytokine and vascular calcifying agent) expression by human macrophages in vitro.[125]
This study is significant in terms of the potential inflammatory response to an implanted
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HA coated stent due to the possible generation of HA particles upon stent deployment.
Additionally, a study by Lin et al. demonstrated the ability of HA to stimulate osteogenic
activity in mouse mesenchymal stem cells in vitro as compared to cells grown on
titanium and plastic controls.[126] This was demonstrated by the increased expression of
osteo-specific genes including alkaline phosphatase, type I collagen, and osteocalcin.
Similarly, Sun et al. cultured human mesenchymal stem cells on
hydroxyapatite/tricalcium phosphate double phase ceramic in vitro.[127] The cells
showed increased expression of osteogenic marker genes Runx2, collagen type I,
osteopontin, and osteocalcin.
A number of different in vivo studies have also demonstrated the ability of HA to
stimulate an osteogenic response when implanted both subcutaneously and
intramuscularly in various animal models.[128-132] Yuan et al. implanted HA cylinders
into the dorsal muscle of dogs and observed significant bone formation as early as 30
days, which increased to time, points up to 6 months.[130, 132] Le Nihouannan et al.
injected 1-2 mm biphasic calcium phosphate granules with a 60/40 composition of
hydroxyapatite and beta-tricalcium phosphate into the dorsal muscles of sheep to evaluate
their osteogenic potential.[131] At 6 months, ectopic bone formation was observed with
trabeculae between the particles similar in size and number to those observed in
spongious bone indicating the ability of the injected particles to stimulate mature bone
formation.
The exact mechanism by which implanted HA stimulates bone formation in vivo
remains unclear. De Groot suggested that there is a concentration of endogenous bone
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morphogenic protein (BMP) accumulated at the ceramic surface that triggers stem cells to
form bone tissue.[131, 133, 134] This concentration of BMP at the surface of implanted
HA was further supported in a study by Yaun et al.[135] This study investigated the
ability of calcium phosphate ceramics to absorb BMP both in vitro and in vivo. The in
vitro study showed HA to have the strongest absorption ability compared to the other
calcium phosphate ceramics tested binding all of the BMP in the test solution within 2
hrs. This absorbed BMP could not be effectively washed from the surface using distilled
water or a calcium chloride solution, but was removed by washing with a phosphate
buffer indicating that BMP may bind to Ca2+ in calcium phosphate ceramics. In the in
vivo porcine study, the polymorphic cells and organic matrix on the surface of the HA
pores stained positive for BMP as did some of the cells within the pores. Additionally,
the amount of new bone formed was increased by pre-treating the ceramics with BMP
prior to implantation.[135]
Another possible explanation for the observed osteogenic response to implanted
HA is the dissolution of the ceramic surface and release of calcium phosphate ions.[131,
136, 137] A study by Reynolds et al. demonstrated extensive calcification of human
VSMCs in response to the addition of exogenous calcium phosphate at 24 hours
compared to a control in standard DMEM.[138] Similarly, Jono et al. showed in vitro
calcification of human VSMC in response to the addition of inorganic phosphate to
standard DMEM at concentrations as low as 2 mmol/L Pi compared to the normal serum
concentration of 1.4 mmol/L Pi.[139] Interestingly, this calcification response was not
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observed in mouse NIH3T3 fibroblasts or bovine aortic endothelial cells with Pi
concentrations as high as 10 mmol/L.
Alkaline phosphatase (ALP) has been well linked to bone mineralization for more
than eighty years. Recently however, VSMC calcification has been somewhat linked to
ALP expression.[140, 141] ALP is a hydrolase enzyme responsible for
dephosphorylating a number of different molecules and thus liberating more free
inorganic phosphate previously indicated to lead to increased vascular calcification. It is
one of the first genes expressed during the process of calcification. Additionally, the use
of ALP inhibitors has been shown to inhibit vascular calcification in vitro [140]. Thus, it
is often used as a marker for vascular calcification.
The present study was aimed at evaluating the performance of HA as a possible
stent coating the three main areas. First, we wished to evaluate the purity of the HA
coating as well as it resistance to cracking and flaking upon straining of the stent.
Secondly, VSMC phenotypic response to the HA coating was evaluated through the
assessment of DNA synthesis and α-actin expression. Finally, we investigated the
osteogenic potential of the HA coating through examination of a number of different
osteogenic markers such as expression of ALP, osteopontin expression, and cellular
calcification.
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5.2a Characterization of HA Coating
Materials and Methods
HA Coating of Nitinol Stent Specimens
As shown in Figure 5-1, Nitinol stents (Cook Biomedical, Bloomington, IN) were
spray coated with a thin HA film (EnBio, CoCork, Ireland) using a novel proprietary
CoBlast procedure. Briefly, the stent surface was simultaneously blasted with two
powders, an abrasive and a dopant, from two separate Venturi style nozzles. In our case,
apatitic MCD (100 µm, Himed Inc., NY), which is a form of sintered calcium
phosphates, served as the abrasive. The dopant was hydroxyapatite [Ca10(PO4)6(OH)2]
powder (25-60µm, S.A.I., Lyon, France). The process takes advantage of the inherent
reactivity of titanium rich surfaces in order to firmly bond the doping agent.
Preparation and HA Coating of 316L Stainless Steel Specimens
Stainless steel specimens were prepared as described in previous work from our
lab.[103] Briefly, annealed 316L stainless steel specimens (Brown metal company,
Rancho Cucamongo, CA) 1.5 cm in diameter were divided into two groups
electropolished (EP) and hydroxyapatite coated (HA). Team Metal Finishing of Toccoa
Georgia performed electropolishing of specimens. HA coating of specimens was carried
out as described previously for the Nitinol stent specimens (EnBio, CoCork, Ireland).
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Figure 5-1: Schematic of CoBlast Coating Procedure Resulting in HA Deposition on
Outer Surface of Stent Struts
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EDS Analysis of HA Coating
Electron dispersive x-rays (EDS, Model S-3400N, Hitachi, Japan) were used to
gain a quantitative breakdown of elements on the sample stent surface. This was done in
order to ensure the purity of the HA surface coating with an appropriate
calcium/phosphorous ratio.
Post-Strain Integrity of HA Coating
The integrity of the HA coating is of particular interest due to the brittle nature of
HA. The effect of deployment-induced strains on HA coating integrity was investigated.
Stent specimens were strained at levels similar to those that would be encountered upon
placing a stent into its retention sheath on the guide wire. This was achieved by
constructing a glass extrusion tip using a 2 ml glass pipette by first heating one end of the
pipette to its melting point with a propane torch, and then pinching it closed in order to
seal the end of the pipette. After the pipette was allowed to cool, the middle portion was
heated to its melting point while gently blowing air into the open end resulting in an
expansion of the heated portion. The pipette was then allowed to cool and the glass was
trimmed to form a small funnel-shaped extrusion tip. The HA coated stent was then
forced through the extrusion tip in order to tentatively simulate strains that would likely
be encountered during the packaging and implantation processes.
Following the straining procedure for the HA coated stents, the integrity of the
coating was then analyzed by scanning electron microscopy (SEM, Model S-3400,
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Hitachi, Japan). This was done in order to visually inspect the HA coating for possible
cracking and flaking.

5.3b Cell Response to HA Coating
Materials and Methods
Cell Culture
In this IACUC approved study, rat vascular smooth muscle cells (VSMC) were
isolated from the aortas of Sprague-Dawley female rats between 6-10 weeks of age
(Appendix C) and maintained with Dulbecco’s Modification of Eagle Medium (DMEM)
(Mediatech, Inc., 10-013-CV, Herndon, VA) supplemented with 10% heat inactivated
Fetal Bovine Serum (FBS) (Sigma-Aldrich, F-4135, St. Louis, MO) and 1% AntibioticAntimycotic (Sigma-Aldrich, A5955, St. Louis, MO). Experiments were carried out
between passages 4-8. For experimental testing, cells were trypsinized using 0.25%
Trypsin containing 0.2 mg/mL EDTA (Sigma Chemical Company, E6511, St. Louis,
MO).
Cell Seeding for Dynamic Mechanical Testing
Silicone membranes were cut into circles 5.25 cm in diameter for each culture
plate out of biomedical grade silicone sheets (Lot SM04106803, Specialty
Manufacturing, Inc. Saginaw, MI) .015" in thickness and 40 durometer Shore A. The
cut silicone sheets were then cleaned using sonication in deionized water and press fit
into the culture plates using a inner Lexan ring. The culture plates were then autoclaved
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(Tuttnauer Brinkmann, 3870M, Jerusalem, Israel) at 121 degrees Celsius for 30 minutes
and put into their appropriate place in the main body of the simulator. The assembled
system was then UV sterilized for 3 hours. The Teflon rings were sonicated in a 1%
detergent solution (Liquinox Critical Cleaning Detergent, Alconox, Jersey City, NJ) for
15 minutes followed by three rinses with DI water. They were then autoclaved and
centered on the Lexan post on top of the silicone membrane. The area inside of the
Teflon rings was then coated with Type I Collagen (Purecol 3mg/ml, Advanced
Biomatrix, lot# 1356) diluted with sterile DI water. The coated membranes were rinsed
with 1.0 ml of Dulbecco’s Phosphate Buffered Saline (DPBS) (Media Tech, Inc., 21-031
CM, Herndon, VA) before cell seeding. Cell counting was done using a Millipore
ScepterTM cell counter, and cells were seeded at a density of 6 x 104 cells suspended in
1.5 ml culture media per plate, and incubated for 48 hours to allow the cells to attach.
The vascular simulator described presently was comprised of two simulator
bodies with each body having three independent channels, which thereby allowed for six
samples independent from one another.[29] In order to mimic the in vivo mechanical
environment, cells were subjected to stimulation from cyclic strain. Equibiaxial strain
was applied to cells cultured on the silicone membrane by applying vacuum suction to
stretch the membrane over the central post. Silicone lubricant was applied on top of the
post in order to reduce friction between the membrane and post. The vacuum pressure
was controlled using Flexcell 3000 software in order to apply a 5% cyclical strain to the
membranes at a rate of 1 Hz. This level of strain is representative of physiological
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conditions in which the vessel wall experiences strains that are generally lower than 10%
and may be as low as 0-4%.[102, 142-144]
The present study consisted of four groups each containing three samples and
repeated in duplicate. These groups were comprised of a control group (Ctrl) in which no
wire was placed, a hydroxyapatite coated Nitinol stent group (HA), a non-coated asreceived Nitinol stent group (NiTi), and a sham wire placement group in which a noncoated Nitinol stent specimen was placed for a duration of 5-10 seconds and then
removed in an effort to separate the effect of injury incurred during stent placement from
that of stent contact on the VSMCs. Dynamic experiments were carried out at time
points of 25 hrs and 5 days to judge the changing cellular response over time.
Cell Seeding for Static Testing
Contrary to the other experiments carried out in the present study, analysis of
VSMC calcification was carried out under static conditions using the stainless steel disks.
For this experiment, the disks were first clean by sonication in 100% isopropyl alcohol
for a duration of 15 minutes. Following this, the disks were rinsed in de-ionized water
and again sonicated for a duration of 20 minutes in a 5% detergent solution (Liquinox,
Alcon Inc.). Finally, disks were subjected to three 15-minute ultrasonic rinses in deionized water with complete water changes at each rinsing interval. The specimens were
then sterilized using standard 12 hr ethylene oxide sterilization (AN 74i Anproline Gas
Sterilizer, Andersen Products Inc.).
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DNA Synthesis
After mechanical stimulation, DNA synthesis was evaluated via an ELISA based
bromodeoxyuridine (BrdU) incorporation assay (Roche). Briefly, cells were BrdU
labeled for a duration of 2 hours after which they were fixed in the provided
fixation/DNA denaturation solution for 30 minutes. Following this, the cells were
incubated with an enzyme linked anti-BrdU antibody solution for 90 minutes. After
several rinses, the cells were then incubated with a substrate solution for 30 minutes, and
the absorbance was read at 370 nm with a reference wavelength of 492 nm. The
remaining cells were then lysed using a 1% Triton X-100 solution and the total protein
content quantified via BCA assay in order to normalize the absorbance values.
Expression of α-Actin
The expression of α-actin was measured using a slight modification of an
established ELISA assay (Appendix D).[103] Briefly, the cells were PBS rinsed and
fixed in a 2% paraformaldehyde solution. The cells were then covered with 1ml blocking
solution (47ml PBS, 2g bovine serum albumin, 3ml FBS, and 25µl Triton X-100) for 45
minutes at room temperature. They were then treated with the primary mouse anti-αactin antibody diluted 1:200 for 2 hrs at RT, followed by a 2hr treatment with a
biotinylated mouse IgG secondary antibody diluted 1:200. The cells were then incubated
for 45 minutes at 37 °C with a streptavidin conjugated alkaline phosphatase diluted 1:500
in TBST buffer (pH 8). Finally, the cells were incubated with the subtrate solution (3mM
pNp, 0.05 M Na2CO3, 0.05 mM MgCl2) for 45 minutes at 37 °C and the absorbance read
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at 405 nm. The cells were then lysed using a 1% Triton X-100 solution and total protein
measured using BCA in order to normalize the absorbance values.
Expression of Osteopontin
Following the 24 hr duration of the experiment, the media was removed, and the
cells were fixed in a 2% paraformaldehyde solution. The cells were then covered with
1ml blocking solution (47ml PBS, 2g bovine serum albumin, 3ml goat serum, and 25µl
Triton X) for 30 minutes at room temperature. They were then treated with the primary
rabbit anti-osteopontin antibody (ab46794) for 12 hrs at 4 °C, followed by a 2hr treatment
with goat anti-rabbit secondary antibody (ab60319). The cells were then DAPI stained to
assist in distinguishing individual cells after imaging. Imaging was done using
fluorescent microscopy (Nikon Inc., Diaphot 300, Melville, NY).
Expression of Alkaline Phosphatase (ALP)
At 24 hrs, the cell culture media was removed and cells were rinsed 2x with PBS
to remove any residual FBS contained within the media. Cells were then lysed by adding
300 ul of a 1% Triton-X 100 solution in PBS per plate for 15 minutes. The cell lysates
were then removed and stored at -80 °C. ALP expression was evaluated using the
colorimetric QuantioChrom Alkaline Phosphatase Assay Kit (Dalp-250, BioAssay
Systems). Absorbances were read at 405 nm at times t=0 and 4 min. This data was then
used to calculate ALP activity in units of IU/L. Total protein content of the sample was
then read using a BCA assay to normalize the data to total protein content. Additionally,
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7F2 osteoblasts cultured under static conditions on tissue culture treated polystyrene
served as a positive control to validate the method.
Smooth Muscle Cell Calcification
In order to further evaluate the possible osteogenic potential of the VSMCs in
response to the HA coating, it was desired to evaluate any possible calcification of the
cells in response to the coating. In order to do this, it was more desireable to culture the
VSCMs for a longer time point. This was achieved by the culture of VSMCs on HAcoated 316L stainless steel disks.
This experiment was divided into three groups: hydroxyapatite coated 316L
stainless steel (HA), electropolished non-coated 316L stainless steel (SS), and a tissue
culture treated polystyrene control (Ctrl). Rat VSMCs were seeded at a density of 3x104
cells per replicate. 7F2 osteoblasts (OB) seeded at a density of 3x104 cells per replicate
on tissue culture treated polystyrene served as a positive control. The cells were then
cultured for a duration of 14 days with media changed every third day. For the VSMCs,
DMEM (Cellgro 10-013-CV, 10% FBS, 1% Ab/Am) media was used, whereas α-MEM
(Cellgro 10-022-CV, 10%FBS, 1% Ab/Am) was used for osteoblast culture.
Calcium depostion of the cells was done using the QuantiChrom Calcium Assay
Kit (DICA-500, BioAssay Systems). Briefly, cells were first lysed using a 500 ul of a
1% Triton-X 100 solution in PBS, and extracellular matrix deposition was removed
through scraping using a cell scraper. Cell lysates were then collected and decalcified by
adding 30ul of stock 12M HCl solution per sample for 24 hrs at 4 °C. Total protein was
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quantfied using BCA in order to normalize Ca concentration values. In order to increase
Ca concentration values to those within the linear range of the assay method, samples
were then dried and reconstituted using 25ul deionized water prior to testing.
Statistical Analysis
All data was evaluated using an ANOVA statistical analysis paired with Tukey
analysis. This was done using SigmaStat statistical analysis software (Systat Software,
Inc., San Jose, CA) with p<0.05 indicating a significant difference.

5.4 Results
5.4a Characterization of HA Coating
EDS Analysis of Surface Coating
The EDS spectra, shown in Figure 5-2, yielded observable peaks for both calcium
and phosphorus. Additionally the calcium/phosphorus ratio was calculated to be
approximately 1.57:1.
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Element

Weight %

Weight % σ

Atomic %

Carbon

9.916

0.095

30.666

Oxygen

5.130

0.074

11.911

Silicon

0.840

0.046

1.111

Phosphorus

0.464

0.062

0.556

Sulfur

0.799

0.075

0.926

Calcium

0.729

0.366

0.676

Iron

67.751

0.335

45.063

Nickel

14.371

0.196

9.092

Figure 5-2: EDS Spectra for HA Coated Stents
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Post-Strain Integrity of HA Coating
The post-strain integrity of the HA coating was evaluated through visual
observation. The HA coated stent surfaces were SEM imaged at magnifications of up to
600x post strain. As can be seen in Figures 5-3 and 5-4, there was very limited cracking
or chipping of the coating as compared to the pre-strain stents.
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Figure 5-3: SEM Images of As-Received (AR) HA Coated Stents Pre-Strain at 30x (a),
200x (b), and 600x (c)
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Figure 5-4: SEM Images of HA Coated Stents Post-Strain at 30x (a), 200x (b), and 600x
(c)
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5.4b Cell Response
DNA Synthesis
DNA synthesis was evaluated using a colorimetric BrdU assay (Roche) at 24 hour
and 5 day time points. The experiments consisted of four different groups at each of
these time points. These groups were a control group in which no wire was placed (Ctrl),
a hydroxyapatite coated Nitinol group (HA), a non-coated Nitinol group (NiTi), and a
sham wire group (Sham). In the sham group, a non-coated Nitinol wire was placed on
the cells for approximately 5 seconds prior to mechanical stimulation in an effort to
separate the cellular response to the presence of the implant from the cellular response to
injury.
At the 24 hr time point, a significant increase in DNA synthesis, as evaluated by
BrdU incorporation, was seen in the HA group (P=<.001), the NiTi group (P=0.005), as
compared to the control. However, no significant difference was observed between the
Ctrl and Sham groups (P=0.097). Additionally, no significant difference was observed
between the HA and NiTi groups (P=0.286).
At 5 days, overall DNA synthesis was greatly reduced compared to the 24 hr time
point for both the HA and NiTi groups. DNA synthesis for the Ctrl and Sham groups at 5
days was not significantly different to that at 24 hrs. Additionally, a significant increase
in BrdU incorporation was again observed for the HA (P=0.007) and NiTi (P=0.001)
experimental groups as compared to the 5 day control. As before, there was no
significant difference between the Ctrl and Sham groups at 5 days (P=0.152).
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Figure 5-5: BrdU Assay of 24 hr (Blue) and 5 day (Red) Studies (*, **, # indicate a
significant difference with P< 0.05)

Expression of α-Actin
At 24 hrs, α-actin expression was significantly decreased for both the HA
(P=0.005) and NiTi (P=< .001) groups as compared to the control. Additionally, no
significant difference was observed between the Ctrl and Sham groups (P=0.148).
Furthermore, no significant difference was observed between the HA and NiTi groups
(P=0.303),
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At the 5 day time point, both the HA group (P=0.004) as well as the NiTi group
(P=0.002) exhibited a significant decrease in α-actin expression as compared to the
control. Similarly to the 24 hour time point, there was no significant difference between
the HA group compared to the NiTi group (P=0.812). Additionally, no significant
difference was observed between the Ctrl and Sham groups (P=0.609).
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Figure 5-6: α-Actin ELISA Assay of Cyclically Strained VSMC at 24 hrs (Blue) and 5
Days (Red) (*, # indicate a significant difference as compared to the control with P<
0.05)
Expression of Osteopontin
There was no observable osteopontin staining in any of the VSMC experimental
groups employed in the present study. However, there was detectable concentration of
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osteopontin present in the 7F2 OB positive control group thereby verifying the method.
Representative images are shown in Figure 5-7.
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b	
  

Figure 5-7: Osteopontin Immunostaining of VSMCs Exposed to HA Coated Stent Under
Dynamic Strain Conditions (a) and 7F2 OB Cells Cultured Under Static Conditions for
24 hrs (b)
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Expression of Alkaline Phosphatase
As illustrated in Figure 5-8 a, following exposure to in vitro strain for 24 hrs, both
the HA coated stent group as well as the non-coated NiTi group showed a significant
increase in ALP activity as compared to the Ctrl group (P=0.008 and 0.03 respectively).
However, no significant difference was observed between the two groups. Figure 5-8 b
shows the same data for ALP expression in VSMCs compared to ALP expression
observed for the 7F2 OB positive control, which demonstrated a significantly higher ALP
expression compared to any of the other groups (P<0.001).
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Figure 5-8: ALP Activity of VSMCs Cultured Under Dynamic Strain Conditions In
Vitro for Stented Groups Compared to a Non-Stented Control (a) and All Experimental
Groups Compared to a 7F2 OB Positive Control (b) (* indicates a significant difference
as compared to the control with P< 0.05)
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Smooth Muscle Cell Calcification
For all of the VSMC groups tested, total calcium content was below the limit of
detection for the method at 0.08 mg/dL. However, the method was verified using the 7F2
OB control. This indicates that over a time period of 14 days, there was no detectible
increase in VSMC calcification in response to any of the treatments tested.

5.5 Discussion
EDS Analysis of Surface Coating
Results from the EDS analysis showed observable peaks for both calcium and
phosphorus. This indicated that there was in fact an intact HA coating on the surface of
the stent struts. Additionally, the calcium/phosphorus ratio was calculated at
approximately 1.57:1, which is quite close to values observed for HA coated implants by
others in the literature. [145, 146] This demonstrated that the surface was in fact coated
with the desired dopant during the previously described coating procedure.
Post-Strain Integrity of HA Coating
In this experiment, we wished to subject the coated wires to levels of strain
representative of those encountered during stent implantation. The purpose of this was to
evaluate the integrity of the HA coating post implantation. After the coated stents were
strained, they were then evaluated visually using SEM. Results showed very little
cracking and/or flaking of the HA coating post strain. This was likely due to several
features of our HA coating. First, the coating method used was not a simple adhesive
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coating process that would allow for possible de-lamination of large portions of the
coating if the adhesive were to fail. Rather, the coating was achieved through the
coblasting procedure described previously. This procedure results in the HA dopant
being chemically bonded to the Nitinol surface. Secondly, the coating method used
resulted in a very thin layer of HA deposited on the surface allowing it to flex somewhat
with the stent reducing the likelihood of damage to the coating upon application of strain.
These results indicated that the HA coating method used resulted in a surface coating that
is very likely to be able to survive the rigorous strain environment encountered upon stent
deployment in vivo.
DNA Synthesis
At 24 hrs DNA synthesis was significantly increased for both the HA and NiTi
groups as compared to the control. Furthermore, no significant difference was observed
between the Ctrl and Sham groups. This indicated that at 24 hrs, the proliferative cellular
response as observed by an increase in DNA synthesis was most likely due primarily to
model strut contact rather than purely the cellular response to injury. Additionally, with
respect to DNA synthesis as an indicator of cellular proliferation, the HA coating
appeared to have little to no effect on the cells compared to the non-coated Nitinol stent
as no difference in DNA synthesis was observed between the two groups.
These results demonstrate that there was an acute response to the implanted stent
specimens at 24 hours. While this response was somewhat attenuated at 5 days, the
effect of continued contact remained apparent. At both time points, there was no
observed difference between the non-coated and HA-coated Nitinol specimens indicating
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that the HA-coated specimen was equally biocompatible to the standard non-coated
specimen with respect to cellular proliferation as indicated by DNA synthesis.
Expression of α-Actin
At 24 hrs results showed a significant decrease in α-actin expression for both the
HA and NiTi groups compared to the Ctrl. Similar to the results from DNA synthesis,
there was no significant difference observed between the HA and NiTi groups indicating
that the HA coating had little effect on the VSMCs and was no more influential on the
cells than the bare non-coated Nitinol stent specimen. These results again held true at the
5 day time point. Furthermore, no significant difference was observed between the 24 hr
and 5 day time points.
These results indicated that similar to the DNA synthesis, α-actin expression
appeared to be unaffected by the applied HA surface coating. However, in contrast to the
increase in DNA synthesis observed in the previous experiment, the decrease in α-actin
expression observed appeared to be less time dependent. Over the course of the 5-day
experiment, α-actin expression did not increase significantly compared to the 24 hr
experiment.
Expression of Osteopontin
In addition to being expressed by native osteoblasts, osteoponin is an osteogenic
marker known to be present in high levels at calcification sites in atherosclerotic lesions
but not in normal arteries.[147] Additionally, osteopontin mRNA has been shown to be
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expressed in smooth muscle-derived foam cells in human atherosclerotic lesions in the
aorta.[148]
There was no positive osteopontin staining observed in any of the VSMC
experimental groups employed in the present study. However, the 7F2 OB positive
control group did stain positive for osteopontin. This indicated that the failure of the
procedure to immunostain the experimental groups was likely a result of a lack of
osteopontin protein being expressed rather than a failure of the staining method. These
results demonstrate that osteopontin expression, as a positive marker for a cellular
osteogenic phenotypic shift, is not stimulated as a result of VSMCs cultured in contact
with HA coated Nitinol in the present dynamic simulator.
Expression of Alkaline Phosphatase
Results from the ALP assay showed a significant increase in ALP expression in
response to placement of both the HA coated and bare NiTi stents as compared to the
Ctrl; however, no significant difference was observed between the HA and bare NiTi
groups. This data suggests that the increased in ALP activity was in response to the
contact of the stent material as well as any possible injury incurred upon its placement.
This response appeared to be independent of stent coating. This increase in ALP
expression in response to stent contact could shed some light on the patterns of
calcification that are observed around areas of increased stress in stented arteries in
vivo.[149] However, as seen in Figure 5-8 b, levels of ALP activity observed post stent
implantation were still quite low in comparison to those observed for fully the
differentiated 7F2 osteoblast positive control indicating that, while ALP expression was
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increased, it is still much below a level that should be considered indicative of a shift to
an osteogenic phenotype.
Smooth Muscle Cell Calcification
The evaluation of calcium depositions showed total calcium content to be below
the limit of detection for the method. However, the method was verified using a 7F2 OB
control in which calcium level were found to be well within the range of the method at
the same time point thereby validating the method. This indicates that over a time period
of 10 days, there was no detectible increase in VSMC calcification in response to any of
the treatments tested. These results indicate that the present HA coating has a negligible,
if any, effect on VSMC calcification.
Results from the present study demonstrated good in vitro biocompatibility of
hydroxyapatite as a possible stent coating. However, the in vivo use of hydroxyapatite as
a biomaterial coating for devices exposed to blood flow may be a cause for some concern
due to HA’s inherent thrombogenicity caused by rapid binding of large amounts of
protein to the surface and platelet aggregation.[150, 151] Hydroxyapatite has been
shown to bind more serum proteins than either titanium or steel.[152] While the
exposure of HA to blood flow may the cause for some concern in the construction of a
vascular stent, this is alleviated in the present case by coating only the outer surface of
the stent with HA. Because the HA coating is present only on the outer surface of the
stent struts, as shown in Figure 5-1, upon implantation in vivo, the struts would imbed
into the vessel wall thereby preventing continuous contact of the HA coating with
circulating blood and reducing concern for extensive thrombotic formation.
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5.6 Conclusion
Overall, the DNA synthesis results indicate that there was a significant increase in
DNA synthesis in response to contact of VSMCs with implanted stents in vitro. This
increase in DNA synthesis was somewhat attenuated at 5 days, but still remained
significant. The lack of difference between the wire groups and the sham groups indicate
that with respect to DNA synthesis, the HA coated sample wires seemed to be well
tolerated and did not illicit an enhanced proliferative response beyond that of the noncoated Nitinol stent specimens.
In our previous corrosion studies, we demonstrated the ability of Ni ions released
during Nitinol corrosion to significantly influence α-actin expression in VSMCs. In a
long term study, the sealing effect of the HA coating would likely prevent this
phenomenon; however, in our short term study, there was most likely not enough Ni ions
released from the bare Nitinol surface to cause a significant effect. The altered actin
expression compared to the control group was primarily due to contact from the strut.
This was demonstrated by the fact that there was no significant difference between the
HA coated and non-coated groups at either 24 hrs or 5 days. This indicates that the
response to the implanted stent was rapid and somewhat stable over the course of 1-5
days. Additionally, in the sham group where the stent specimen was removed, actin
levels returned to levels within one standard deviation of the control group within 24 hrs.
This indicates that the decreased α-actin expression was an effect of the continued contact
of the stent with the VSMCs rather than a response to injury from implantation.
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Results also showed a significant increase in ALP expression in response to
contact from the model stent specimen. This response seemed to be as a direct result of
contact forces and injury incurred upon stent placement. The increase in ALP expression
was independent of material coating.
While no increase of in vitro VSMC calcification was observed in our present
experiments, it should be noted that calcification is a slow process that may take up to
several weeks to develop in an in vitro model. Future experiments should employ longer
time points out to approximately 30 days to allow a more subtle response to reach
measurable levels. However, the use of a positive control in our experiment showed that
at 10 days, fully differentiated osteoblasts could calcify to detectable levels using our
present method. This illustrates there was no acute osteogenic response to the HA
coating.
Overall, the results of this study addressed three main concerns involving the use
of hydroxyapatite as novel stent coating. First, we demonstrated the purity and post
strain integrity of the coating using EDS and SEM respectively. This indicated that we
did in fact have a pure HA coating capable of withstanding strains representative of those
encountered upon stent deployment. Secondly, we evaluated VSMC phenotypic response
to the coating. We demonstrated that under dynamic culture conditions, HA-coated
Nitinol stents appeared to be equally biocompatible compared to non-coated Nitinol
stents. Finally, we investigated whether HA would trigger a calcific/osteogenic response
in VSMCs by evaluating the evaluation of the expression of osteopontin, ALP, and
calcification. The results showed no detectible increase in either osteopontin or
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calcification. While ALP expression was increased as compared to the control, it was not
significantly different from the non-coated Nitinol group. Overall, the results of this
study demonstrate that hydroxyapatite may serve as a durable and biocompatible stent
coating capable of possibly serving as a favorable drug delivery platform. The feasibility
of using HA as a vehicle for the local delivery of bisphosphonate class drugs such as
alendronate for the control of VSMC proliferation was evaluated further in Appendix E.
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-CONCLUSION-

The project hypothesis was that smooth muscle cell hyperplasia, as an important
causative factor for vascular restenosis following endovascular stent deployment, was
triggered by the various effects of stent strut contact on the vessel wall including contact
forces and material biocompatibility. This project was evaluated in several ways:
In aim 1, contact forces of the model stent strut wire were simulated using the
finite element method in order to more fully characterize the mechanical environment
cells are subjected to inside the vascular simulator. Additionally a static proof-of-concept
in vitro study demonstrated a synthetic phenotypic response of VSMCs to the implanted
Nitinol wire typical of what could be expected in vivo.
In aim 2, VSMC response to Nitinol corrosion ions was evaluated using clinically
significant nickel ion concentrations from Nitinol wires corroded in a simulated in vivo
environment. Results illustrated that nickel ion concentrations below those capable of
affecting cellular proliferation have a significant affect on VSMC morphology and αactin expression under static in vitro culture conditions. These results shed some light on
one possible source of stimulation leading to a synthetic phenotypic VSMC response in
the stented artery.
Aim 3 evaluated VSMC response to a model stent strut under dynamic in vitro
culture conditions of concurrent cyclic strain and flow shear. This study was aimed to
elucidate any possible differential response to Nitinol wire samples as compared to 316L
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stainless steel. Results from this study showed a synthetic phenotypic response to both
materials illustrated by an increase in DNA synthesis coupled with a decrease in α-actin
expression further validating our model of the stented artery. Importantly, there was no
observable differential response to the Nitinol specimen compared to 316L stainless steel.
These results suggest that, in vitro, Nitinol is equally biocompatible with the VSMCs
with respect to changes in cellular phenotype compared to the traditionally accepted gold
standard of 316L stainless steel.
Next, aim 4 evaluated the use of hydroxyapatite as a stent strut coating for use as
a possible drug delivery platform. This study had a number of different goals:
First, we evaluated the HA coating itself. EDS analysis of the surface
demonstrated that the surface was in fact coated with a thin layer of hydroxyapatite
having an calcium/phosphorus ratio on par with other studies available in the literature
for hydroxyapatite implants. Additionally, as illustrated through SEM analysis of the
surface, post strain integrity of the coating was excellent with minimal cracking or
flaking.
Next we evaluated any possible osteogenic potential of the coating as well as cell
phenotypic response. Results showed the HA coating to have a quite minimal osteogenic
potential on VSMCs. This was demonstrated by a lack of osteopontin immunostaining as
well as cellular calcification. While ALP expression was slightly elevated, it was still
vastly lower that ALP expression levels demonstrated by the 7F2 osteoblast positive
control. Cellular phenotype studies evaluating DNA synthesis and α-actin expression
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demonstrated no significant difference in either assay between HA-coated and bare
Nitinol stent specimens.
Results from this in vitro study demonstrated that hydroxyapatite is a
biocompatible stent coating that does not illicit a significant osteogenic response from
VSMCs. Additionally, there was no significant difference in phenotypic response
compared to a non-coated stent. These results suggest hydroxyapatite is a biocompatible
coating that could serve as a favorable drug delivery platform for the inhibition of stent
restenosis.
Overall, this project was able to demonstrate that an increase in VSMC
proliferation as well changes in phenotypic indicators such as decreased α-actin
expression and cell aspect ratio are induced through model stent strut contact in vitro.
Additionally, it was shown that, with respect to known biocompatible materials such as
Nitinol and 316L stainless steel, DNA synthesis and α-actin expression are independent
of stent material composition. Together, these results indicate that the nickel-titanium
alloy Nitinol is equally biocompatible under dynamic in vitro culture conditions to the
traditional gold standard material for vascular stent construction, 316L stainless steel.
Furthermore, hydroxyapatite was shown to be biocompatible stent surface coating with
acceptable post-strain integrity. In a feasibility study given in Appendix E, this coating
was also shown to be capable of serving as a favorable drug delivery platform capable of
reliably delivering locally therapeutic doses of bisphosphonates such as alendronate to
control VSMC proliferation in an in vitro model of a stented blood vessel. This stent
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coating/drug combination may be effective for reducing restenosis as a result of VSMC
hyperplasia in vivo.
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-PROJECT RECOMMENDATIONS-

1. Evaluating the Response of Various Cells Types.
The present project evaluated the response of vascular smooth muscle cells from
Sprague Dawley rats exclusively. This was done due to the fact that the majority of
the bulk of neointimal tissue of restenotic stented blood vessels is composed by
VSMCs of a synthetic phenotype and their extracellular matrix; however, it is
important to not overlook the importance of the endothelial layer. While it is known
that there is a significant denudation of the endothelial layer upon stent deployment, a
number of these important signaling cells do remain present at the stenting site.
Endothelial cells are known to significantly influence VSMC response in vivo by
releasing a number of different signaling molecules. Therefore, the response of the
endothelial cells to the same stimuli used in the present study is an important factor
contributing to the development of in-stent restenosis that should not be overlooked.
2. Evaluation of Other Stent Coatings.
For our current project, we evaluated cell response to our HA coating only. It
would be beneficial to investigate the in vitro response of other possible drug eluting
coatings to illustrate any possible benefits of the HA coating. For example, it would
be advantageous to evaluate our HA coating as compared to a coating such as (polyL-lactic acid) PLLA which releases proinflammatory lactic acid. While were able to
demonstrate that HA does not illicit a significant differential in phenotypic response
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as compared to a non-coated bare metal specimen, it would be prudent to see how HA
compares to other stent coatings investigated in the literature using our dynamic
model.
3. Evaluation of Other Bisphosphonate Drugs
Our HA coating is capable of binding any one of the numerous
bisphosphonate drugs currently available on the market. In the present study,
alendronate was chosen because it was readily available and relatively
inexpensive. However, alendronate is not the most potent member in the family
of nitrogen containing bisphosphonate drugs. This study should be repeated
utilizing the more potent zolendronate. By utilizing a more potent drug, it may be
possible to deliver the drug at an effective local concentration over a longer
period of time in vivo. Additionally, the drug release profile experiment should
be repeated using much longer time points in order to evaluate what the long term
drug delivery profile will be.
4. In Vivo Modeling
The present in vitro model has been developed in order to investigate the
synthetic response of VSMCs in response to the placement of a model stent strut.
The model was designed to incorporate important mechanical stimuli such as
cyclical strain and shear in order to mimic to in vivo environment. The use of in
vitro modeling is valuable because of the ability to reduce variability of
experimental data compared to in vivo studies; however, it neglects to account for
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important responses to implantation in the body such as the inflammatory and
immunological response. For this reason, in order to progress in the development
of bisphosphonate-eluting HA coated stents, it is important to incorporate the use
of an in vivo animal model.
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-APPENDICES-
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-APPENDIX ABlood Vessel Biology and Atherosclerosis

Blood Vessel Biology
The blood vessel is divided into three primary layers or tunics: the intima, media,
and adventitia.[1, 6] These layers are separated by the internal elastic lamina (IEL) and
external elastic lamina (EEL) respectively. The primary differences between arteries and
veins are the valve-like projections of the intima present in the veins of the extremities to
prevent backflow as well as the more pronounced muscular medial layer in the artery.
The intima is a simple squamous epithelium known as the endothelium.[153] It is
comprised primarily of endothelial cells (ECs). However, there may also be a few
scattered vascular smooth muscle cells which will from here on be simply referred to as
smooth muscle cells (SMCs) as well as a small number of macrophages.[154] The media
is comprised of primarily SMCs as well as elastic connective tissue whereas the
adventitia is made up of fibrous connective tissue with a few scattered cells. These layers
will be discussed in more detail in the paragraphs that follow.
The endothelium is a very thin monolayer of cells that serves a variety of
purposes in the vasculature. Its primary purpose is to serve as a hydrophilic, nonthrombogenic lining of the blood vessels as well as a selectively permeable diffusive
barrier.[6] However, despite its importance, it is so thin that its existence was denied
until 1865.[155] In contrast, when considering the endothelium as a whole, it makes up
the largest endocrine unit in the body weighing in at approximately one kilogram.[155] It
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is this endocrine function that is of very high importance in regulation of vascular
function.
The most obvious function of the endothelium is the prevention of blood
coagulation and thrombus formation. This is accomplished in part by the so-called
“smoothness” of the endothelial surface thereby preventing activation of the intrinsic
clotting mechanism.[1] The cell surface also expresses a layer of the
mucopolysaccharide glycocalyx which acts to repel platelets and clotting factors. The
protein thrombomodulin is also bound to the cell surface and serves to bind with
thrombin thereby slowing the coagulation cascade. In addition, the thrombomodulinthrombin complex activates the plasma protein known as protein C that inactivates
activated Factors V and VIII in the coagulation cascade.[1] The endothelium performs a
rather complex secretory function. Among the molecules it secretes are collagen and
elastin, clotting or anti-coagulant factors, prostaglandins, cytokines, vasodilators and
vasoconstrictors including endothelin and nitric oxide (EDRF), free radicals, and
important cell adhesion molecules such as VCAM-1.[6, 155].
The media is comprised of primarily smooth muscle cells and extracellular
matrix.[6] It is arranged in such a way that there are layers of similarly oriented SMCs
interlaced with collagen type III fibers such that the fibers tighten around the cells as the
vessel wall is put under tension. This thereby holds the group of cells together preventing
excessive stretching or slippage. Each subunit of cells, known as a fascicle, is also
surrounded by similarly oriented elastin fibers forming the effective unit of medial
structure that is known as a musculoelastic fascicle.[6] Each of these fascicles is oriented
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in a direction parallel to the imposed tensile stress in the vessel wall which results in an
alignment perpendicular to blood flow. Arteries can be divided into two basic categories,
either elastic or muscular. The larger elastic arteries include the aorta as well as its larger
proximal branches.[6] The arteries of main concern in occlusive vascular disease are the
smaller muscular arteries. These arteries have generally less collagen and elastin fibers
when compared to elastic arteries and are more densely populated by smooth muscle
cells. This allows muscular arteries to control blood flow by rapidly constricting or
dilating.[1, 6, 72]
The adventitia is what is known as a fibrocellular connective tissue.[6] It is a
layered structure composed of both collagen and elastin. It also contains a network of
vasa vasorum to nourish the medial SMCs as well as nerves that help to mediate SMC
contraction and tone.[6] The adventitia is distinguished by the presence of fibroblasts and
less organized collagen/elastin.[156] It also serves to help provide mechanical support to
the vessel wall.
Smooth Muscle Cells
The most abundant cell type in an artery is the smooth muscle cell. Interestingly,
smooth muscle cells exhibit phenotypic plasticity in response to stimuli in a phenomenon
known as modulation [72, 155, 157] as first confirmed in vitro by Chamley-Cambell et
al. in 1979.[158] They are the only cells of the myogenic lineage with this ability.[157]
The two ends of the spectrum for SMC phenotype are contractile and synthetic.[154, 157]
It is important to note that the differentiation state of SMCs is in fact a spectrum where
cells may exist in any number of differentiation states between the two ends. It is not a
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simple black and white issue with cells being easily distinguished into one phenotype or
the other. Healthy adult SMCs are primarily of the differentiated contractile
phenotype.[72, 143] Their contractile ability is important for the maintenance of blood
vessel tone as well as regulation of blood pressure and flow.[1, 6, 72] They exhibit
properties such as low synthetic activity, low proliferation rate, and expression of unique
contractile proteins such as smooth muscle α-actin, myosin heavy chain, h-caldesmon,
and calponin.[72, 143, 159] The most abundant of these proteins is α-actin, making up
approximately 40% of the total cell protein.[159]
Highly synthetic SMCs can be referred to as “immature” and exhibit
characteristics such as increased proliferation, increased organelles for production of
lipids and proteins, and increased excretion of extracellular matrix as well as increased
migration.[72, 157, 159] They are also characterized by increased expression of the
proteins vimentin and β-actin.[160-162] In addition, the cells lose their contractile ability
which is confirmed by staining for contractile markers such as smooth muscle α-actin,
myosin heavy chain, h-caldesmon, and calponin.[72, 159, 161] Synthetic SMCs also
exhibit altered morphology when examined under a microscope. Contractile SMCs are
smaller, elongated, and spindle shaped when compared to a synthetic SMC’s
hypertrophic appearance surrounded by copious extracellular matrix production. It is
important to note that SMCs will eventually progress toward a more synthetic phenotype
when cultured in vitro so it is important to carry out experimentation under low passage
numbers.
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As mentioned previously, SMCs of a contractile phenotype are generally referred
to as a “healthy” phenotype because they are present in healthy adult arteries. On the
other hand, SMCs of a highly synthetic phenotype present in vivo are generally indicative
of diseased conditions. In addition to excessive extracellular matrix production, synthetic
SMCs can also release cytokines which are chemotactic for other SMCs, induce cell
proliferation, and can stimulate phenotypic change from contractile to synthetic.[6]
Pathology of Atherosclerosis
The basic pathology of atherosclerosis is characterized by the development of a
growth of cells and connective tissue with a soft lipid-rich core known as an
atheromatous plaque.[154] This lesion can eventually grow to occlude the lumen causing
complications such as obstruction to blood flow, thrombosis risk, loss of elasticity, and
impaired contractility. The development and progression of these lesions will be
discussed later. Atherosclerosis is also characterized by a chronic inflammatory
response. [154, 163]
The initial cause of atherosclerotic development has been the cause of some
debate. The two commonly accepted theories can be referred to as the “fatty streak
theory” and the “response to injury theory”. However, these theories are not mutually
exclusive. In both cases, high blood triglyceride levels, particularly low density
lipoproteins (LDLs), are the necessary catalyst for lesion development.[1, 143, 154, 163]
The primary difference between the two theories is in the modality of monocyte
recruitment to the lesion site.
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Following the fatty streak theory, fatty streaks develop early in life as a result of
lipid accumulation in the vessel wall caused by a high fat diet as well as genetic
predisposition.[6, 154, 164] Early childhood lesions commonly regress, but may
continue to develop rapidly during the 15-34 year age span.[143, 154] In this process,
LDLs are transported by transcytosis across the endothelium and deposited in the intima
where a small amount may be taken up by local SMCs.[143] However, the LDLs may
become oxidized during the process of transcytosis thereby forming the toxic oxLDL. It
is this injurious oxLDL that is thought to damage neighboring cells thereby triggering the
inflammatory response.[164] This results in local macrophage infiltration from nearby
tissues as well as monocyte recruitment from the blood. The resulting macrophage
population then phagocytizes the LDL. The resulting lipid filled macrophages and SMCs
form what are known as foam cells that are characteristic of atherosclerotic lesions.
The response to injury theory varies in that the inflammatory response is thought to be
initiated by some sort of initial injury to the endothelium. This can be caused by factors
such as smoking, high blood pressure, infection, etc.[6] The damaged endothelium
promotes platelet adhesion and subsequent release of platelet derived growth factor
(PDGF) as well as monocyte recruitment. PDGF has been shown to be both chemotactic
and mitogenic for SMCs.[14] The damaged endothelium also exhibits altered
permeability leading to lipid accumulation in the vessel wall in the presence of high lipid
content in the blood. The local macrophages and SMCs will then uptake this lipid
thereby forming foam cells.
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Whatever the initial causation, atherosclerosis is a progressive disease marked by
a chronic inflammatory response. Lesion progression takes place over the course of years
through a series of well documented stages.[165] This is illustrated in Table 3
reproduced from Stary 1992.[165] It is important to note that these stages are not
necessarily linear.
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Table A.1: Classification of Atherosclerotic Lesions [165]
Reommended Terms

Description

Conventional
terms based on
appearance
with the
unaided eye

Comments

Type I

(initial lesion)

Lipoprotein accumulation in intima; lipid in
macrophages; these changes discernible
only microscopically or chemically; no
tissue damage

None

Types I and II are
sometimes combined
as “early lesions”

Type II

(fatty streak)

Fatty Streak

IIa

(progressionprone:colocalized
with specific
adaptive thickening)

Lipoprotein accululation in intima; lipid in
macrophages and smooth muscle cells;
quantities large enough to be visible to the
unaided eye but still no tissue damage

(progression
resistant)
IIb
Type III

(preatheroma)

All type IIa changes plus multiple deposits
of pooled extracellular lipid; microscopic
evidence of tissue damage and disorder

None

An “intermediate” or
“transitional” lesion
had be suspected

Type IV

(atheroma)

All type IIa changes plus confluent mass of
extracellular lipid (lipid core) with massive
structural damage to intima

Fibrous plaque;
fibrolipid
plaque; plaque

Types IV to VIII are
sometimes combined
as “advanced lesions”

Type V

(fibroatheroma)

All type IV changes plus development of
marked collagen and smooth muscle cell
increase (cap) above lipid core

Type VI

(complicated
fibroatheroma)

All type V changes plus a thrombotic
deposit, and /or erosion or fissure

Complicated
plaque

VIa

(thrombohemmorrhagic)

VIb

(thrombotic)

VIc

(hemmorrhagic)

Type VII

(calcific lesion)

Any advanced lesion type composed
predominantly of calcium; substantial
structural deformity

Calcified plaque

Type VIII

(fibrotic lesion)

Any advanced lesion type composed
predominantly of collagen; lipid may be
absent

Fibrous plaque
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In addition to simply growing in size to physically occlude the lumen, the ongoing
progression of a plaque often leads to fissuring and rupture which in turn causes
thrombosis.[166] These thrombi give rise to the serious risk of emboli formation and
subsequent heart attack or stroke. It is important to note that the progression of
atherosclerosis can be clinically silent until the very late stages of plaque formation. This
is the reason for the somewhat common incidences of sudden death from sudden
coronary blockage or stroke caused by emboli arising from atherosclerotic lesions.
Diagnosis of Atherosclerosis
Atherosclerosis is known as the silent killer because it often presents no easily
distinguished symptoms to the patient until it is too late to prevent a major myocardial
infarction or stroke. The physician must consider a number of factors in the initial patient
consultation. As given in Rutherford’s Vascular surgery, the list of steps in this
procedure are as follows: (1) reaching a presumptive diagnosis by the physician based
upon clinical grounds, (2) using noninvasive methods of diagnosis to either confirm the
diagnosis or discern the severity of the condition, (3) weigh the patient’s degree of
disability with the known natural progression of the disease in conjunction with the best
possible treatment against the risk and potential benefit of the various interventional
options, and (4) when it is deemed necessary to intervene, confirming the initial diagnosis
and extent of progression using angiography.[6] It is also important to note that when
percutaneous intervention is the likely modality of treatment following angiographic
confirmation, arrangements should be made in advance such that the surgeon can proceed
with the appropriate treatment procedure at the time of angiography to avoid unnecessary
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additional risk to the patient from a follow up procedure. In order to reach the
presumptive diagnosis of various forms of vascular disease, physicians must evaluate
each patient individually considering all of the possible risk factors as well as detecting
and evaluating any possible symptoms.
In the evaluation of peripheral vascular disease (PVD), diagnosis may be slightly
easier than of obstructions in the coronary arteries. Blockages in the coronary arteries
can be somewhat more difficult to diagnose non-invasively because of anatomical
location. However, the diagnosis of PVD is a marker for coronary artery disease (CAD)
thus it is relevant to discuss the use of the following methods for the eventual diagnosis
of both conditions.[6, 167] PVD in the lower extremities is most commonly marked by
leg pain with exercise known as claudication.[6] This is often described by the patient as
simply a cramp that goes away after a short rest. Not surprisingly, the degree of leg pain
experienced by the patient with the least amount of exercise indicates the severity of the
blockage with severe cases having pain at rest or even ulceration and tissue loss. It is
important to note that claudication can also be caused by a number of conditions other
than restriction of blood flow due to vascular disease. A careful evaluation of various
variables concerning the claudication experienced is valuable in discerning various
conditions responsible for the pain. Pain is the most important tool in a list of symptoms
evaluated upon observation by the physician known as the “five P’s” which are: Pain,
Pallor, Pulselessness, Paresthesias, and Paralysis. However, a grey-blue or purplish tint
known as cyanosis often replaces pallor.[6, 168]
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Following the initial office consultation to gather information about patient
history, risk factors, and obvious symptoms, the physician will then follow up using any
of a number of non invasive diagnostic techniques to further confirm a diagnosis. In the
treatment of PVD, perhaps the easiest of these is the measurement of the patient’s ABI or
Ankle Brachial Index. This is simply a ratio of the blood pressure taken at the patient’s
ankle and the blood pressure taken in the patient’s arm at the brachialis taken bilaterally.
The lower of these two numbers is taken to be the patient’s overall ABI. Generally,
evaluation of an ABI is as follows: between 0.9 and 1.2 is considered normal, between
0.5 and 0.8 for patients with claudication, and between 0 and 0.4 for patients with rest
pain or tissue loss.[169] However, ABI may be limited for evaluating patients with less
severe degrees of stenosis or those with calcified arteries.[170]
Following the simple methods stated previously, the next most commonly
employed non invasive techniques are duplex scanning followed by computed
tomography (CT) and magnetic resonance imaging (MRI).[6] The most commonly
employed of these methods is duplex scanning.
A duplex scan is the combination of a B-mode scan with the use of pulsed
Doppler.[171, 172] It can provide very important information about the degree and exact
location of an occlusion. The B-mode gives a black and white image of the walls of the
blood vessel and the Doppler measures blood velocity. In areas where the vessel is
narrowed by an occlusion, the cross sectional area is decreased such that there is a local
increase in flow velocity in order to maintain flow. The Doppler portion of the duplex
scan utilizes color to give the operator easily decipherable information about direction of
126
	
  

flow. This is useful in detecting things such as areas of turbulent flow or veins with
incompetent valves allowing excessive backflow.
Angiography is the final tool employed prior to surgical intervention, and it is the
principal tool for the evaluation of coronary stenoses.[4, 173] It is the gold standard to
which other diagnostic techniques are compared for the diagnosis of nearly all forms of
occlusive vascular disease.[172] This procedure is done via the intravascular injection of
a radio opaque contrast dye upstream of the location of the suspected stenosis with the
aid of a catheter. It is then immediately imaged using x-ray. This procedure is performed
immediately prior to percutaneous intervention to confirm the location of the occlusion
and then immediately following the procedure to insure restoration of flow was achieved.
It is important to note that the x-ray scan used for the angiogram is also used to visualize
the stent as it is advanced to the location of the lesion. However, many stents are
somewhat difficult to pick up on the x-ray. For that reason, many stent manufacturers
incorporate radiopaque gold markers on the ends of the stent as a solution to visualization
problems.
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-APPENDIX BEffect of Various Mechanical Stimuli Applied to Cells In Vitro Effect of Strain on
Smooth Muscle Cells

Although a number of approaches for the exposure of cells to strains exist, the
most popular experimental setups use vacuum suction to the bottom of a flexible
membrane on which cells are cultured. [73, 76, 77, 174] Some of these systems are able
to produce approximately equibiaxial strain to which cells are subjected during
experiments while other systems generate non-uniform distributions of applied strain.
[73, 102, 175]
The exposure of SMCs to cyclic strain has been shown to increase cell
proliferation and induce a shift toward a synthetic phenotype in some experiments [7377] while preventing cell proliferation and promoting a contractile phenotype expression
in others.[142, 176-178] However, efforts to explain the phenomenon governing these
observations regarding SMC response have been the cause of some debate. On initial
observation, the underlying reasons for these discrepancies in results may be unclear.
However, upon closer evaluation these results can be roughly separated into two groups:
those stretched at high and low strain rates with the separation point being approximately
10%. For example, Hipper et al. cyclically stretched SMCs of the A10 cell line derived
from the aortas of embryonic rats grown on type I collagen coated membranes at 0.5 Hz
using 5% elongation.[142] This resulted in decreased DNA synthesis of 30% at 24 hrs
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and 50% at 48 hrs compared to a static control.[142] This observation remained
unaffected when the experiment was repeated on laminin and pronectin coated
membranes. Chapman et al. used flow cytometry to show that cyclic stretch of type I
collage coated membranes prevented rat aortic VSMC proliferation via a G1/S phase
transition inhibition using strain levels of 10% at 1 Hz compared to a static control.[176]
In contrast, Mills et al. found that cyclic stretching of the type I collagen coated culture
substrate ( 24% at the edges and 7% in the center) caused increased bovine aortic VSMC
proliferation and cyclic adenosine monophosphate (cAMP) accumulation compared to
static controls.[77] Hasaneen et al. subjected human airway SMCs grown on type I
collagen coated membranes to cyclic strain between 17-18.5% and observed increased
SMC proliferation at 3 and 5 days compared to a static control.[73] Additionally, the
conditioned media from the strain group contained elevated levels of matrix
metalloproteinase-1 (MMP-1), MMP-3, and both pro and activated MMP-2 likely
indicating an increase in SMC migration. This increase in cyclically strained SMC
migration compared to statically cultured SMCs was then confirmed using a modified
Boyden chamber assay that operates based on counting the number of cells able to
migrate through a gelatin coated membrane. Addition of the broad spectrum MMP
inhibitor Prinomastat prevented this increase in proliferation and migration while also
inhibiting MMP-2 activation in a dose dependent manner.
Physiological levels of strain in vivo are generally less than 10% and may be as
low as 0-4% depending on the location in the vasculature.[102, 142-144] The previously
mentioned studies by Mills, Hu, and Sotoudeh show that SMC proliferation and de129
	
  

differentiation into a synthetic phenotype is enhanced by high strain. This may explain
the fact that high blood pressure, and thus increased force on the vessel wall and
increased strain by as much as 15%, causes thickening of the blood vessel wall due in
part to SMC proliferation in vivo.[76, 78, 179, 180] In addition, it has been observed that
high levels of strain experienced during balloon angioplasty also leads to varying degrees
of restenosis caused by SMC proliferation. Together, it can be concluded that the
maintenance of healthy contractile SMCs with low proliferation rates is achieved by
closely mimicking the physiological strain level experienced in vivo while deviations
from this normal mechanical environment lead to a shift towards a synthetic phenotype.
Effects of Fluid Shear Stress on Endothelial Cells and Smooth Muscle Cells
A number of different custom-designed systems have been devised in order to
stimulate cells with the use of fluid shear. These systems generally break down into two
basic design configurations: the cone and plate system and the parallel plate flow
chamber.[175] In the cone model, variations in angular velocity of the cone provide
kinematic control of fluid shear stress on the cells under investigation. The parallel plate
setup uses a simple pressure differential between the inlet and outlet to drive cell culture
media across the culture area. This can be achieved via either gravity heads or active
pumps. The parallel plate setup is advantageous in that the entrance length can be
designed to allow the development of a laminar flow proximal to the culture area thereby
providing a highly homogeneous stress stimulus.
In vivo, the artery is lined by a monolayer of highly hemophilic endothelial cells
in direct contact with blood. Subsequently, SMCs are not directly exposed to fluid shear
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from blood flow. However, following the deployment of a vascular sent, it is common to
experience a near complete denudation of the endothelial layer thereby exposing the
underlying SMCs and thrombogenic collagen and sub-endothelial matrix.[4, 12] The
restoration of this endothelial layer is important for the recovery of the artery to its native
state preventing late thrombosis and reducing restenosis.[4] For this reason, much of the
work available in the literature focuses on the exposure of endothelial cells (ECs) to fluid
shear in vitro. In the stented artery model by Punchard et al., a vascular stent was
deployed inside a fibronectin coated silicone tube seeded with human umbilical cord
ECs.[181] It was hypothesized that the turbulent areas of flow caused by the stent struts,
along with cell injury from the stent strut, was a major contributing factor to the observed
increased expression of genes by ECs for E-Selectin, inter-cellular adhesion molecule-1
(ICAM-1), and VCAM-1. [181] Lin et al. utilized bovine ECs exposed to laminar shear
stress for 24 hrs using a parallel plate flow chamber, and observed an increase in the
expression of the tumor suppressor gene p53.[182] The transcription factor p53 can be
activated in a number of different cell types in response to various stresses such as UV
and ionizing radiation, DNA-damaging agents, and hypoxia.[182, 183] It is known to
lead to the induction of various growth arrest genes such as p21cip1 as well as the DNA
damage inducible gene 45 (GADD45) thereby leading to growth inhibition.

This

increase in p53 expression was observed at shear stress levels of 3 dynes/cm2 and higher,
but not at 1.5 dynes/cm2.[182] These results indicate that the threshold of growth
inhibition for ECs caused by shear stress may lie between 1.5 and 3 dynes/cm2. This is
further supported by the work of Akimoto et al. that found an inhibition of DNA
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synthesis in bovine aortic ECs subjected to shear stress levels of 30 and 5 dynes/cm2
compared to a static control, but no significant inhibition was observed at 1
dyne/cm2.[184]
Following an angioplasty procedure, it is common to observe a denudation of the
endothelial layer thereby directly exposing the underlying SMCs to shear stress from
blood flow. The direct stimulation of SMCs with shear stress in vitro is done in order to
model this situation. Asada et al. stimulated bovine SMCs using orbital shear stress
levels of 11.5 dynes/cm2 and observed increased proliferation as well as decreased αactin and calponin expression along with increased expression of vimentin and β-actin
compared to a static control.[185] In another study, bovine SMCs were stimulated with
oscillatory shear stress of 14 dynes/cm2 using an orbital shaker by Haga et al. which
resulted in a significant increase in cell number and 3[H]thymidine incorporation
compared to a static control at 5 days.[186] Moreover, Qi et al. demonstrated a decreased
expression of protein Rho-GDP dissociation inhibitor alpha (Rho-GDIα) in rat aortic
SMCs exposed to low levels of shear stress (5 dynes/cm2) as compared to those exposed
to higher levels of shear stress (15 dynes/cm2).[187] Since decreased Rho-GDIα
expression has been associated with enhanced vascular SMC migration and apoptosis in
SMCs, this molecule may become a drug target in the development of future
pharmaceutical treatments to reduce SMC migration and vascular remodeling following
angioplasty in vivo.
It can be seen from evaluating these and a number of other studies that, shear
stress plays an important role in the activity of both ECs and SMCs. In both cases, there
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is threshold level at which shear stress acts to inhibit cell proliferation. At higher levels
of shear stress of approximately 15-28 dynes/cm2, which is within the normal range of
physiologic shear stress of 5-25 dynes/cm2, SMC proliferation is reduced.[188, 189] The
shear level at which EC proliferation is inhibited in vitro is much lower at approximately
1.5-3 dynes/cm2.[149, 182, 184]
Effect of Combined Strain and Fluid Shear on Endothelial and Smooth Muscle Cells
Exposure of SMCs to concurrent fluid shear and cyclic strain stimuli adds another
level of complexity to modeling of the in vivo environment experienced by SMCs in an
artery following the denudation of the endothelial layer. The development of
experimental setups to apply controlled shear stress and equibiaxial strain could lead to
cost effective and time efficient test systems with a much higher degree of reproducibility
than that observed using in vivo experimentation. To date, however, few experimental
models are available to evaluate the combined effect of these two stimuli applied
simultaneously.
To the best of our knowledge, the earliest example of such an in vitro study was
reported by Moore et al.[144] This device made use of compliant silicone tubes coated
with fibronectin and seeded with bovine pulmonary endothelial cells and allowed to reach
confluence. After which, they were subjected to pulsatile pressurized flow in order to
apply both cyclic stretch and fluid shear. Although it was not reported, based on the
design it can be speculated that cell seeding inside the tube as well as visualization of
adherent cells would be problematic. This general test setup, however has been used by
several groups to test the response of ECs to cyclic stretch and fluid shear.[190-192] For
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example, Zhao et al. observed a significantly elongated morphology as well as an
orientation in the direction of flow and perpendicular to stretch in bovine aortic
endothelial cells seeded in fibronectin coated Sylgard tubes subjected to shear stress
greater than 2 dynes/cm2 or hoop stress greater than 2% at 24 hrs compared to a static
control.[192] The formation of stress fibers aligned with the long axis of the cell was
induced by both shear stress as well as hoop stress. Stress fiber size and alignment were
significantly enhanced by the concurrent application of shear and hoop stress as
compared to application of either stimuli singularly indicating a possible synergistic
effect between the two stimuli on the cell morphology of ECs.
Another 3D vascular simulator that utilized a silicone compliant tube was
developed by Punchard et al.[181, 193] This study differed from the previously
mentioned compliant tube studies in that a Libertè bare metal stent (Boston Scientific
Corporation, USA) was deployed inside the silicone tube using a balloon catheter in order
to evaluate the effects of the deployed stent on human umbilical cord vein endothelial
cells (HUVECs) in vitro.[181] The group observed local endothelial denudation
immediately after stent deployment at 15 atm for 30 seconds as a result of physical
damage to the cell layer.[181] Additionally, the HUVECs subjected to flow without a
deployed stent oriented themselves in the direction of flow. Patterns of cell orientation
were less apparent in the stented model subjected to flow and completely randomized in
the stented model not subjected to flow indicating a possible response of ECs to regions
of turbulent flow caused by stent struts.[181] Furthermore, the deployed stent increased
the expression of E-Selectin, ICAM-1, and VCAM-1 by the ECs 24 hrs following stent
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deployment.[181] While these studies highlight the effects of fluid shear and cyclic
strain on ECs, little is known about the effects of combined cyclic strain and fluid shear
on SMCs.
The work of Acampora et al. conducted in our laboratory utilized a parallel plate
flow chamber combined with computer controlled vacuum pressure to strain a silicone
membrane across a stationary post in order to provide independently controlled fluid
shear and cyclic strain stimuli.[102] Using this setup, Acampora et al. for the first time
exposed rat aortic SMC to a stain stimulus (two cycles of 12% strain) to mimic
angioplasty injury followed by combined strain and fluid shear (4% and 0.5 dynes/ cm2
respectively) to mimic physiological hemodynamic conditions. This study demonstrated
a 75% increase in SMC proliferation compared to the dynamic control not subjected to
the 12% strain injury at a time point of 8 hrs.[102] Additionally, the authors reported a
19% decrease in the expression of the contractile marker smooth muscle α-actin in the
angioplasty injury model compared to a static control.[102] In a follow up study when
cells were subjected to similar concurrent strain and shear conditions for 24 hrs, rat aortic
SMC proliferation, expression of the synthetic marker vimentin, cellular apoptosis, and
hypertrophy were all observed higher compared to the group stimulated with cyclic strain
alone.[194] Interestingly, the cells exposed to concurrent cyclic strain and fluid shear
exhibited similar SMC proliferation compared to the cells stimulated with cyclic tension
only. This lack of effect on SMC proliferation and apoptosis is likely due to the low level
of fluid shear (0.5 dynes/cm2) employed in the experiment as it was shown in previous
shear only studies that shear stress levels below approximately 15 dynes/cm2 do not act to
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inhibit SMC proliferation.[185-189] However, the increased expression of the synthetic
marker vimentin in the Acampora angioplasty injury model subjected to concurrent shear
and strain demonstrates that there may be a synergistic effect on synthetic marker
expression from concurrent force application.[195] Previous studies in the literature have
shown decreased contractile marker expression and increased vimentin expression
independently in response to oscillations shear stress and strain compared to static
controls, the Acampora study was the first to illustrate the important additive effects of
shear and tensile forces.
The experimental setup developed by Acampora et al. also allowed investigation
of cell response to various pharmacologic treatments encountered during vascular
intervention. For example, the authors investigated the effect of combined shear and
strain in the presence of heparin, an anticoagulant commonly administered during
angioplasty procedures.[29] In addition to its properties as an anticoagulant, heparin has
also been shown to decrease SMC migration and proliferation.[29, 196, 197] A common
clinical protocol is to administer a three to five minute 10,000 unit bolus IV injection of
heparin immediately prior to balloon angioplasty.[198] When simulated in vitro, this
10,000 unit bolus injection of heparin was held in contact with the cells for 5 min
followed by a 100 µg/ml heparin dosage for 24 hrs and resulted in decreased rat aortic
SMC proliferation.[29] Thus, the aim of the study by Acampora et al. was to test the
efficacy of the drug treatment in minimizing intimal hyperplasia following balloon injury.
Furthermore, Fasciano et al. demonstrated a decrease in rat SMC proliferation using 100
µg/ml heparin under static conditions as compared to a negative control.[199] This was
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thought to be due to a block in the G1 to S phase caused by an inhibition of cyclindependent kinase 2 activity. This is in agreement with other studies reported in the
literature in which SMC proliferation decreased following heparin administration.[29,
196, 199-202] A unique finding in the Acampora study was the differential expression of
calponin, a calcium binding protein that inhibits the ATPase activity of myosin, in
response to changes in mechanical environment.[29] It was shown that the cells
subjected to concurrent strain and fluid shear in the presence of heparin exhibited
decreased calponin expression compared to a static control. However, heparin
administration to static SMCs increased calponin expression compared to a static
control.[29] The results of this study highlight the differences in calponin expression by
SMCs in response to certain stimuli under varying culture conditions. This differential
cell response clearly illustrates the need for such a dynamic simulator in order to
investigate the possibility of other varying SMC responses to pharmaceutical treatments
as a result of mechanical environment. This is necessary in order to gather experimental
data more likely to mirror the in vivo response and thus be of significant value in the
clinical realm.
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-APPENDIX CRat Aortic Smooth Muscle Cell Isolation Protocol

Modified Rat Vascular SMC Primary Isolation protocol based on a pooling of advice
from Dr. Aggie Simionescu, Dr. Jiro Nagatomi, and Dr. Anand Ramamurthi as well as
several additions based on first-hand experience
1. Euthanize adult Sprague-Dawley rats by CO2 asphyxiation as per established
animal protocol guidelines.
2. Split the abdomen longitudinally from the pelvis all the way through the rib cage.
3. Carefully dissect away the internal organs to expose the aorta along the posterior
abdominal wall.
4. Clip aorta at the pelvic bifurcation and dissect it away from the dorsal abdominal
wall to the aortic arch.
5. Flush aorta with approximately 3ml of cold transport medium using via
hypodermic injection through the wall of the left ventricle.
Note: it is important that the aorta be dissected away from the dorsal abdominal
cavity prior to flushing as blood present in the aorta is beneficial for visualization of
the artery.
6. Clip the aorta at the aortic arch and place into ice cold transport medium
(DMEM+100ug/ml pen/strep+2ug/ml fungizone) for transport back to lab.
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7. Peel away excess fat and adventitial layer using two pair of sterile tweezers using
a dissection microscope under a laminar flow hood on a sterile petri dish with a
small amount of PBS added to prevent drying and maintain cell viability.
Note: Adipose tissue is easily distinguished by the glistening appearance of the
contained fat globules. Adventitial tissue will appear as a somewhat ragged
yellowish-white tough material covering the outside of the artery. The exposed
medial layer will appear as a clean pink tube.
8. After removing all excess fat and adventitial tissue, carefully trim away any larger
arterioles from the aorta to prevent later endothelial contamination in the culture.
9. Split aortic segments lengthwise and lay them open with the intima facing
upward.
10. Use a sterile scalpel to scrape away the endothelial layer.
Note: The very thin endothelial layer is not distinguishable under such low
magnification. However it is important to thoroughly but gently scrape the entire
intimal surface to remove this cell layer. Very little pressure is required.
11. Rinse aortic segments in PBS to remove any loose cells on the surface.
12. Finely mince aortic segments into approximately 0.5mm pieces under
magnification using sterile scissors.
13. Place minced artery segments in 15ml tube containing 10ml DMEM/protease
solution comprised of 10ml DMEM +10mg collagenase type II (Worthington
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Biomedical) +2.5mg Elastase (Worthington Biomedical)+ 1.5mg soybean trypsin
inhibitor (Worthington Biomedical).
14. Incubate for 20-25 min at 37C gently inverting tube 2-3 times about every 5
minutes to mix.
15. Allow aortal segments to settle to bottom of tube and carefully aspirate the
digestion solution.
16. Resuspend in 10ml DMEM+10% FBS+100ug/ml Pen/Strep to dilute and
deactivate the digestion solution.
17. Use a sterile scalpel blade or fine tipped tweezers to lightly scratch a small
asterisk shaped pattern on bottom of each well in a six well plate to aid in
adhesion of tissue segments.
18. Remove arterial segments using sterile tweezers and plate approximately 4 pieces
into each well directly atop the approximate center of the scratched pattern. (Two
pairs of tweezers may be required as the segments tend to clump together and may
need to be gently pulled apart.)
19. Supplement segments with a single drop of DMEM+FBS+pen/strep to keep them
moist and viable without allowing them to float away from the surface.
20. Incubated plates for 24 hrs to allow adhesion and then supplement with 1.5ml
additional media being careful not to dislodge the attached tissue.
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21. Incubate for approximately 7-10 days or until cells can be seen growing away
from the tissue segments in several “patches”.
Note: It is important to change the media every approximately 2-3 days for the initial
growth period regardless of the small number of viable cells present to remove any
toxins from the breakdown of the non viable portions of the tissue. Special care must
be taken not to dislodge or remove the tissue segments.
22. When the “patches” of adherent cells (not the entire well surface) reach
confluence, the tissue segments are then carefully removed and the cells passaged
and sub-cultured normally.
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-APPENDIX DCell-Based ELISA Assay Protocol for the Evaluation of Cellular α-Actin Content

1. Fix VSMCs on plates with 1 ml 2% paraformaldehyde for 20 minutes at RT.
2. Rinse wells with PBS 2x to remove paraformaldehyde.
3. Block with 1 ml blocking agent (2gm BSA, 3ml FBS, 25µ TritonX-100, and 47ml
PBS) for 45 minutes at RT.
4. Add primary antibody to smooth muscle α-actin (diluted 1:200 in blocking agent)
for 2 hours at RT.
Note: Negative control group received blocking agent without any primary antibody
for the same time.
5. Rinse with PBS 3x for 5 minutes each to remove any unbound antibody.
6. Add biotinylated mouse IgG (diluted 1:200 in blocking agent) for 2 hours at RT.
7. Rinse with PBS three times waiting 5 minutes in each washing step to remove any
unbound antibody.
8. Incubate with streptavidin conjugated alkaline phosphatases (diluted 1:500 in
TBST at pH8) for 45 minutes at 37oC.
9. Rinse with PBS 3x for 5 minutes to remove any unbound enzyme.
10. Incubate with 500 µl chromogenic substrate (3 mM p-nitrophenyl phosphate, 0.05
M Na2CO3, and 0.05 mM MgCI2) for 45 minutes at 37oC.
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11. Transfer 125µl of colored product from each well to a 96 well plate in triplicate
and measure absorbance at 405 nm.
12. Rinse cells with PBS 2x to remove pnpp and add 350 µl 1% Triton-X 100
solution diluted in PBS for 20 minutes
13. Remove cell lysates and store at -80C for BCA assay to normalize absorbance
values to total protein content
14. Subtract absorbance of respective negative controls from their experimental
counterparts and normalize against protein content.
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-APPENDIX EAnalysis of Hydroxyapatite as a Novel Drug Eluting Stent Coating to Control VSMC
Proliferation Under Dynamic Culture Conditions In Vitro

E.1 Introduction
Drug eluting stents have been shown to significantly decrease the incidence of in
stent restenosis. Delivery of the drug directly to the site where is needed allows for a
therapeutic dose at the stenting site while maintaining very low systemic concentrations.
These combine in order to illicit a more favorable response following implantation into
the body with the ultimate goal of preventing restenosis caused by intimal hyperplasia.
Drug eluting stents have been shown to greatly reduce the incidence of in-stent
restenosis.[107, 203, 204] The only two drugs currently on the market with FDA
approval for widespread use with drug eluting stents are Sirolimus (Cypher stent) [112]
and Paclitaxel (Taxus stent) [108]. However, Medtronic is currently developing a
Zotarolimus drug eluting version of their Driver stent under the name Endeavor.[111]
Other research groups are looking at a number of other immunosuppressant and antiinflammatory drugs for use with DESs such as rapamycin [205, 206], biolimus A9 [207,
208], cyclosporine A [209], everolimus [210-212], methylprednisolone [213, 214], and
dexamethasone [113, 215] just to name a few. However, while some experimental drugs
have proven more effective than others in certain applications, the main problem
associated with DESs that are currently on the market lies not in the efficacy of the drug
in preventing VSMC hyperplasia. Rather, while somewhat rare, a few patients receiving
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DESs suffer from issues such as incidences of late thrombosis, and incomplete stent
apposition.[107] This is thought to be primarily due to the fact that the locally high drug
administration causes an inhibition of the body’s natural healing response following stent
implantation.[107] The lack of tissue in-growth causes incomplete apposition of the stent
and delayed re-endothelialization. This results in an increased risk for late thrombosis
and myocardial infarction following the discontinuation of anti-thrombotic medications.
[107, 204, 216]
Recently, some researchers have investigated the off label use of drugs such as
bisphosphonates (BPs) to manage SMC proliferation and migration. [217-220]
Traditionally, bisphosphonates are used for the treatment of osteoporosis. They serve to
increase bone mineral density by inhibiting osteoclast activity as well as limiting
apoptosis of both osteoblasts and osteocytes.[221] The inhibitory effect of nitrogencontaining BPs such as alendronate on osteoclasts is thought to be due to preventing
protein prenylation.[222] In vivo, BPs bind to hydroxyapatite in the bone thereby
preventing them from being rapidly cleared from the blood as well as inhibiting HA
resorption thereby inhibiting bone turnover.[223] In addition to osteoclast deactivation,
this effect is thought to be due in part to the inactivation of monocytes and macrophages.
[219]
Addtionally, BPs have been shown to inhibit the development of atherosclerotic
lesions in vivo. Bisphosphonates have also been shown to inhibit LDL accumulation and
degradation in macrophage cultures thereby inhibiting foam cell formation.[220]
Furthermore, BPs are known to inhibit in vivo atherogenesis and calcification without
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affecting serum cholesterol or calcium.[224, 225] Injection of liposomal alendronate has
been shown to reduce neointimal hyperplasia in a rabbit model after intravascular stent
deployment.[226] Table D.1 reproduced from a review by Ylitalo et al shows results
from a number in animal studies demonstrating the ability of various bisphosphonate
drugs to inhibit atherosclerotic development and progression. Additionally,
bisphosphonates form a very rapid and stable bond with hydroxyapatite present in bone.
In fact, the terminal skeletal half-life of alendronate in man is estimated at approximately
10 years. [220, 227, 228] This stable binding ability makes hydroxyapatite an excellent
drug delivery platform for bisphosphonates.
This study was aimed at the evaluation of the previously described HA coating as
a drug delivery platform for bisphosphonate-class drugs such alendronate sodium.
Additionally, we wished to evaluate the efficacy of locally delivered alendronate at
attenuating the proliferative response of VSMCs following implantation of a model stent
strut under dynamic culture conditions in vitro.
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Table E.1: Effect of Bisphosphonates on Experimental Atherosclerosis [220]

Drug	
  
Etidronate	
  (5	
  
mg/kg/day	
  sc)	
  for	
  8	
  
weeks[229,	
  230]	
  

Animal	
  Model	
  
Rabbit	
  fed	
  peanut	
  oil	
  and	
  
cholesterol	
  for	
  8	
  weeks	
  before	
  
drug	
  treatment,	
  
preestablished	
  atherosclerosis	
  

Results	
  
Reduced	
  the	
  amount	
  of	
  lesions	
  and	
  
accumulation	
  of	
  lipids,	
  calcium,	
  
collagen,	
  and	
  elastin	
  in	
  aorta	
  during	
  
regression	
  period	
  

Etindronate	
  (2.5	
  
mg/kg/day	
  sc)[225]	
  

Rabbits	
  fed	
  cholesterol,	
  
nicotine,	
  and	
  vitamin	
  D	
  for	
  12	
  
weeks	
  

Reduced	
  the	
  calcification	
  of	
  aorta	
  and	
  
the	
  amount	
  of	
  lipid	
  lesions	
  in	
  arteries;	
  
inhibited	
  thromboarteritis	
  and	
  death	
  
rate.	
  

Etidronate	
  (20-‐40	
  
mg/kg/day	
  po)[231]	
  

Rabbits	
  fed	
  peanut	
  oil	
  and	
  
cholesterol	
  and	
  8	
  weeks	
  

Reduced	
  the	
  amount	
  of	
  lesions	
  and	
  
accumulation	
  of	
  lipids,	
  calcium,	
  
collagen,	
  elastin,	
  and	
  
glycoaminoglycans	
  in	
  aorta	
  

Cloronate	
  (5	
  mg/kg/day	
  
sc)[232]	
  

Cynomolgus	
  monkeys	
  fed	
  fat	
  
and	
  cholesterol	
  for	
  6	
  months	
  

Reduced	
  aortic	
  calcification	
  but	
  
increased	
  sudanophilic	
  lesions	
  in	
  
peripheral	
  lesions	
  in	
  peripheral	
  
arteries.	
  

Pamidronate	
  (40	
  
mg/kg)	
  or	
  etidronate	
  
(40-‐120	
  mg/kg)	
  po	
  
daily[233]	
  

Cynomolgus	
  monkeys	
  fed	
  fat	
  
and	
  cholesterol	
  for	
  24	
  months	
  

Inhibited	
  gross	
  and	
  microscopic	
  
atherosclerosis	
  and	
  decreased	
  aortic	
  
calcium,	
  cholesterol,	
  collagen,	
  and	
  
elastin	
  

Etidronate	
  (20	
  
mg/kg/day	
  po)	
  for	
  5	
  
months[234]	
  

Swine	
  fed	
  cholesterol	
  for	
  4	
  
months	
  and	
  aorta	
  injured	
  
before	
  drug	
  treatment,	
  
preestablished	
  atherosclerosis.	
  

Reduced	
  aortic	
  calcification	
  but	
  not	
  
sudanophilic	
  lesion	
  areas	
  and	
  
inhibited	
  lipid-‐rich	
  necrosis	
  of	
  lesions.	
  

Clodronate	
  (25	
  mg/kg	
  
iv)	
  twice	
  a	
  week	
  for	
  12	
  
weeks[235]	
  

Rabbits	
  fed	
  high-‐cholesterol	
  
diet	
  for	
  12	
  weeks	
  and	
  
simultaneously	
  treated	
  with	
  
clodronate.	
  

Reduced	
  the	
  area	
  of	
  visible	
  and	
  lipid-‐
stained	
  atheromatous	
  lesions	
  and	
  
accumulation	
  of	
  lipids	
  and	
  calcium	
  in	
  
aorta.	
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Mechanism	
  Postulated	
  
by	
  Authors	
  
Formation	
  of	
  
lipoprotein-‐
mucopolysaccharide-‐
calcium	
  complexes	
  as	
  
well	
  as	
  their	
  binding	
  to	
  
connective	
  tissue	
  
proteins	
  may	
  be	
  
reduced	
  due	
  to	
  altered	
  
calcium	
  metabolism.	
  	
  
Effects	
  on	
  calcium	
  
metabolism	
  in	
  arterial	
  
wall	
  
Cell	
  proliferation	
  and	
  
mobility,	
  secretion	
  of	
  
connective	
  tissue	
  
proteins,	
  deposition	
  of	
  
calcium	
  in	
  elastica	
  and	
  
cholesterol	
  binding	
  to	
  
elastin	
  protein	
  were	
  
decreased.	
  
Bisphosphonate	
  inhibits	
  
only	
  the	
  advanced	
  form	
  
of	
  atherosclerosis	
  but	
  
not	
  the	
  less	
  severe	
  
disease.	
  
Cell	
  proliferation	
  and	
  
mobility,	
  secretion	
  of	
  
connective	
  tissue	
  
proteins,	
  deposition	
  of	
  
calcium	
  in	
  elastica	
  and	
  
cholesterol	
  binding	
  to	
  
elastin	
  protein	
  were	
  
decreased,	
  which	
  may	
  
be	
  due	
  to	
  effects	
  on	
  
calcium-‐dependent	
  cell	
  
responses.	
  
Inhibition	
  of	
  necrosis	
  
may	
  be	
  due	
  to	
  
prevention	
  of	
  
intracellular	
  calcium	
  
overload	
  and	
  
subsequent	
  cell	
  death.	
  
Inhibition	
  of	
  
accumulation	
  of	
  
atherogenic	
  lipoproteins	
  
in	
  arterial	
  macrophages	
  

E.2 Materials and Methods
Drug loading of HA coated stents
HA coated Nitinol stent specimens were first cleaned by sonication in 100%
isopropyl alcohol for 15 minutes. Following which, they were then sonicated in a 5%
Liquinox solution in milli-Q water for 15 minutes followed by 3 rinses in milli-Q water
with the water being completely changed for each rinse step.
HA stents were then loaded with alendronate by soaking them in a saturated
solution (10 mg/ml) of alendronate sodium dissolved in HPLC grade water for a duration
of 48 hours. Specimens were removed from the soaking solution and allowed to air dry.
Drug Elution	
  
Stent specimens previously loaded with alendronate were placed in 2ml fresh
HPLC-grade water at RT to allow the drug to release from the surface. One ml samples
were then taken between 12 hrs and 5 days. Samples were repeated in triplicate.
There have been a number of different methods for measuring alendronate sodium
using HPLC reported in the literature. However, many of these methods either require
time-intensive ion complexing, or perchloric acid, which is undesirable because of its
flammable, corrosive, and explosive properties. For our pilot experiments, an ion
chromatography method with refractive index detection previously published in the
literature was used [236]. However, because the needed sensitivity could not be achieved
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using this method, another method employing in-line copper II nitrate complexation was
used. [237] A Waters HPLC column with anion-exchange (Milford, MA) was used in the
present method. This column was packed with polymethacrylate resin having a
quaternary ammonium functional group (6µm particles size, 4.6x75mm ID). Additional
parameters were replicated following those previously published [237]: a column
temperature of 25°C, 0.85 mL/minute flow rate, and injection volume of 50µL. It is
important to note that a flow rate of 0.85ml/min was used instead of the 1.0mL/min rate
used in the literature because the manufacturer’s maximum recommended flow rate for
our column was 1.0mL/min. Thus, we selected a slightly lower value in order to insure
we did not exceed the maximum. Dilute nitric acid (Fluka) of 6mM with copper II nitrate
(0.5mM, Alfa Aesar) was used for the mobile phase because it yielded the shortest
alendronate retention time and sharpest peak [237]. Additionally, immediately prior to
the elution experiments, a calibration curve was generated. Over the course of the elution
testing, the same HPLC column was used. Additionally, equilibration of the column was
accomplished through injection of the alendronate standard solution until reproducible
retention times and peaks could be generated. The standard 0.4mg/mL alendronate
solution was formulated by dissolving 40mg of alendronate sodium into 100mL DI
water. The resulting solution was then filtered using a 0.2µm filter (Nalgene) for HPLC
use. Furthermore, individual samples were also filtered using 0.45 µm polypropylene
syringe filters (National Scientific). Experimental analysis showed the alendronate peak
had an approximate retention time of 4 min and a detection level of 0.4µg/mL, which is
similar to detection limit values reported in the literature of approximately 0.3µg/mL
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[237].
	
  
Samples (n=4; triplicate) were analyzed using high pressure liquid
chromatography (HPLC, Waters, Milford, MA) anion exchange using in-line
complexation. A 6mM nitric acid (Fluka) + 1.5mM copper II nitrate (Alfa Aesar) mobile
phase were used which employed a flow rate of 0.85mL/min using a Waters IC-Pak
Anion HR column.
Cell Seeding for Mechanical Testing
Silicone membranes were cut into circles 5.25 cm in diameter for each culture
plate out of biomedical grade silicone sheets (Lot SM04106803, Specialty
Manufacturing, Inc. Saginaw, MI) .015" in thickness and 40 durometer Shore A. The
cut silicone sheets were then cleaned using sonication in deionized water and press fit
into the culture plates using an inner Lexan ring. The culture plates were then autoclaved
(Tuttnauer Brinkmann, 3870M, Jerusalem, Israel) at 121 °C for 30 minutes and put into
their appropriate place in the main body of the simulator. The assembled system was
then UV sterilized for 3 hours. The Teflon rings were sonicated in a 1% detergent
solution (Liquinox Critical Cleaning Detergent, Alconox, Jersey City, NJ) for 15 minutes
followed by three rinses DI water. The rings were then autoclaved and centered on the
Lexan post on top of the silicone membrane. The area inside of the Teflon rings was
coated with Type I Collagen (Purecol 3mg/ml, Advanced Biomatrix, lot# 1356) diluted
with sterile DI water. The coated membranes were rinsed with 1.0 ml of Dulbecco’s
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Phosphate Buffered Saline (DPBS) (Media Tech, Inc., 21-031 CM, Herndon, VA) before
cell seeding. Cell counting was done using a Millipore ScepterTM cell counter, and cells
were seeded at a density of 6 x 104 cells suspended in 1.5 ml culture media per plate, and
incubated for 48 hours to allow the cells to attach.
The vascular simulator employed in the present study was made up of two
independent simulator bodies.[29] Each body has three independent channels, which
thereby allows for six different samples, which are independent from one another. In
order to mimic the mechanical environment experienced in vivo, cells were subjected to a
cyclical strain stimulus. Equibiaxial strain was applied to the silicone membrane via
vacuum suction in order to stretch the membrane over the central Lexan post. Silicone
lubricant was applied on top of the post in order to reduce friction. The vacuum pressure
used to stretch the membrane was controlled using Flexcell 3000 software in order to
apply 5% cyclical strain to the membranes at a rate of 1 Hz. This level of strain is
representative of physiological conditions in which the vessel wall experiences strains
that are generally lower than 10% and may be as low as 0-4%.[102, 142-144]
The study consisted of three groups: an alendronate loaded HA coated stent
(Alendronate), a bare Nitinol stent (NiTi), and a stent free control group (Ctrl). One
group was subjected to stimulation from the HA wire and compared to a control group
without a wire. Each group contained three samples and was repeated in duplicate.
DNA Synthesis
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After mechanical stimulation, DNA synthesis was evaluated via an ELISA based
bromodeoxyuridine (BrdU) incorporation assay (Roche). Briefly, cells were BrdU
labeled for a duration of 2 hours after which they were fixed in the provided
fixation/DNA denaturation solution for 30 minutes. Following this, the cells were
incubated with an enzyme linked anti-BrdU antibody solution for 90 minutes. After
several PBS rinses, the cells were then incubated with a substrate solution for 30 minutes
and absorbance was read at 370 nm with a reference wavelength of 492 nm. The
remaining cells were then lysed using a 1% Triton X-100 solution and the total protein
content quantified via BCA assay in order to normalize the absorbance values.
Expression of α-Actin
The expression of α-actin was measured using a slight modification of an
established ELISA assay (Appendix C).[103] Briefly, the cells were PBS rinsed and
fixed in a 2% paraformaldehyde solution. The cells were then covered with 1ml blocking
solution (47ml PBS, 2g bovine serum albumin, 3ml FBS, and 25µl Triton X-100) for 45
minutes at room temperature. They were then treated with the primary mouse anti-αactin antibody diluted 1:200 for 2 hrs at RT, followed by a 2hr treatment with a
biotinylated mouse IgG secondary antibody diluted 1:200. The cells were then incubated
for 45 minutes at 37 °C with a streptavidin conjugated alkaline phosphatase diluted 1:500
in TBST buffer (pH 8). Finally, the cells were incubated with the subtrate solution (3mM
pNp, 0.05 M Na2CO3, 0.05 mM MgCl2) for 45 minutes at 37 °C and the absorbance read
at 405 nm. The cells were then lysed using a 1% Triton X-100 solution and total protein
measured using BCA in order to normalize the absorbance values.
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Statistical Analysis
All data was evaluated using an ANOVA statistical analysis paired with Tukey
analysis. This was done using SigmaStat statistical analysis software (Systat Software,
Inc., San Jose, CA) with p<0.05 indicating a significant difference.

E.3 Results
Drug Elution
Results from the drug elution study showed an initial burst release from the stent
surface within the first 12 hrs of soaking in HPLC grade water. This amounted to
approximately 13 µg of alendronate released per stent segment. After the 12 hr burst
release, the alendronate concentration in the soaking solution stayed relatively constant
over the course of 5 days. In this study, each time point was repeated in triplicate under
the same preparation; however, the results showed a rather large standard deviation
between the different replicates.
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Figure E-1: HPLC Quantification of Alendronate Released from 0.5-5 Days

DNA Synthesis
As illustrated in Figure 6-2, results from the BrdU assay showed a significant
increase in DNA synthesis as a result of the bare Nitinol stent placement as compared to
the control (P=0.025). However, the alendronate-loaded hydroxyapatite-coated Nitinol
stent group showed a significant decrease in DNA synthesis as compared to the bare
Nitinol stent (P=0.039). In fact, there was almost no observable increase in absorbance
for the alendronate group as compared to the Ctrl group with values remaining within
approximately 5%.
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Figure E-2 : BrdU Assay of Cyclically Strained VSMCs in Response to an AlendronateLoaded, Hydroxyapatite-Coated Nitinol Stent In Vitro (* indicates a significant
difference as compared to the control with P< 0.05)

Expression of α-Actin
As expected based on results from previous studies, there was a significant
decrease in α-actin expression in response to placement of the model stent specimen for
both the alendronate-loaded HA group as well as the HA coating that was not loaded with
alendronate as compared to the control (P=0.026 and 0.02 respectively). However, there
was no significant difference in α-actin expression between the two HA-coated
experimental groups (P=0.65).
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Figure E-3: α-Actin ELISA Assay of Cyclically Strained VSMCs in Response to an
Alendronate-Loaded, Hydroxyapatite-Coated Nitinol Stent In Vitro (* indicates a
significant difference as compared to the control with P< 0.05)

E.4 Discussion
Drug Elution
Results from the elution study showed an initial burst release of alendronate
within the first 12 hrs with a rather large standard deviation between samples. In future
studies, this could be improved by using a larger number of replicates at each time point.
Additionally, using our current method it was not possible to determine the total amount
of alendronate deposited on the stent surface during the 48 hr loading period. This was
due to the fact that the extremely high concentration of alendronate present in our
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aqueous solution used to drug-load our stent segments was above the concentration range
of our study. In future studies, it would be beneficial to measure the alendronate
concentration both before and after drug loading of the stent segment. This would allow
us to determine the total amount of drug present on the hydroxyapatite-coated surface. It
is important to obtain a profile of percent of total drug released over time in order to
determine the length of time our present drug eluting stent would be effective if
implanted in vivo.
DNA Synthesis
As expected based on experience from previous studies, results showed a
significant increase in DNA synthesis as a result of the bare Nitinol stent placement as
compared to the control. More importantly; however, results showed locally delivered
alendronate from the HA coating capable of nearly eliminating this increase in DNA
synthesis resulting in BrdU incorporation levels within 5% of the control group. Overall,
these results indicated that alendronate was capable of significantly attenuating cell
proliferation marked by an increase in DNA synthesis in the present dynamic in vitro
model.
This response may be explained by similar studies present in the literature which
have shown BPs such as risedronate and zolendronate to have antiproliferative effects on
mouse mesothelioma cell lines in vitro marked by a decrease in DNA synthesis.[238]
This was thought to be a result of inducing phosphorylation of the p38 mitogen-activated
protein kinase.[238, 239] Similar to their action on osteoclasts, nitrogen containing BPs
have also been shown to inhibit VSMC proliferation in vitro by preventing G-protein
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prenylation through inhibition of farnesyl pyrophosphate synthase.[240] While their
exact role in triggering VSMC pathogenesis is not exactly known, recent studies have
shown a number of G-protein coupled receptors to be important regulators of SMC
functions such as migration and proliferation.[241-243] Furthermore, in vivo, chronic
inhibition of farnesyl pyrophosphate synthase using alendronate has been shown to
improve endothelial function in spontaneously hypertensive rats marked up an up
regulation of nitric oxide synthase coupled with an inhibition of the G-protein RhoA
activation.[244]
Expression of α-Actin
As expected based on results from previous studies, there was a significant
decrease in α-actin expression in response to placement of the model stent specimen for
both the alendronate-loaded HA group as well as the HA coating that was not loaded with
alendronate as compared to the control; however, no significant difference was observed
between the two groups. These results show that, with regard to the expression of αactin, alendronate has little to no effect on the VSMCs while still maintaining the ability
to significantly reduce DNA synthesis. This is contrary to results observed following
sirolimus and paclitaxel treatment of VSMCs, which showed, in addition to inhibition of
proliferation, a differential expression of important structural proteins such as αactin.[245, 246]
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E.5 Conclusion
Results of the present study showed that alendronate is in fact able to be loaded
on a hydroxyapatite-coated Nitinol stent specimen. HPLC analysis demonstrated an
initial burst release of alendronate within the first 12 hrs. Further investigation is needed
to calculate the total amount of drug loaded on the stent surface in order to determine the
percent released from the stent surface. This is important to evaluate the potential
performance of the drug eluting stent over a longer period of time.
In vitro studies employed in the present work demonstrated that, under dynamic
culture conditions of cyclic strain, alendronate-loaded HA coated stents were effective at
reducing VSMC proliferation. This was marked by a significant decrease in DNA
synthesis as compared to HA coated stents that were not loaded with alendronate.
Additionally, results showed that alendronate did not significantly affect α-actin
expression.
While some further investigation is needed in several areas, results from this
preliminary proof-of-concept study are quite positive. The present study demonstrated
that a Nitinol stent with a hydroxyapatite coating can serve as a drug delivery platform
for the delivery of bisphosphonate drugs such as alendronate. Additionally, it was shown
that alendronate eluded from the surface of the HA-coated stent can be delivered at
concentrations, immediately local to the stent, high enough to inhibit VSMC proliferation
with not significantly affecting α-actin expression. Overall, these results indicate that,
while further investigation is still needed, hydroxyapatite as a favorable drug delivery
platform for the administration of bisphosphonate class drugs such as alendronate may be
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effective as a new class of drug eluting stents for the prevention of in-stent restenosis due
to VSMC hyperplasia.
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